Form 10-Q - Quarterly report [Sections 13 or 15(d)]

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2024

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number: 001-41309

iCoreConnect Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware

86-2462502

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

529 E. Crown Point Road, Suite 250, Ocoee, FL 34761

(Address of principal executive offices) (Zip Code)

(888) 810-7706

(Registrant’s Telephone Number, Including Area Code)

__________________________

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbols(s)

Name of each exchange on

which registered

Common stock, par value $0.0001 per share

ICCT

The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large, accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large, accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated Filer	☒	Smaller reporting company	☒
Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of May 15, 2024 there were 10,240,398 shares of the registrant’s common stock outstanding.

iCoreConnect Inc.

FORM 10-Q QUARTERLY REPORT

FOR THE QUARTER ENDED MARCH 31, 2024

Table of Contents

Part I Financial Information

Item 1	Financial Statements (Unaudited)

	Condensed Consolidated Balance Sheets as of March 31, 2024 (Unaudited) and December 31, 2023	3

	Condensed Consolidated Statements of Operations for the Three Months ended March 31, 2024 and 2023 (Unaudited)	4

	Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit) for the Three Months ended March 31, 2024 and 2023 (Unaudited)	5

	Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2024 and 2023 (Unaudited)	6

	Notes to Condensed Consolidated Financial Statements	7

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	28

Item 3.	Quantitative and Qualitative Disclosures About Market Risks	34

Item 4.	Controls and Procedures	34

Part II Other Information

Item 1.	Legal Proceedings	36

Item 1A.	Risk Factors	36

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	36

Item 3.	Defaults Upon Senior Securities	37

Item 4.	Mine Safety Disclosures	37

Item 5.	Other Information	37

Item 6.	Exhibits	38

Signatures		39

Table of Contents

iCoreConnect Inc.

CONDENSED CONSOLIDATED BALANCE SHEETS

	As of
	March 31,			December 31,
	2024			2023
ASSETS	(unaudited)
Cash	$	138,031		$	1,219,358
Accounts receivable, net		512,148			563,905
Prepaid expenses and other current assets		719,347			1,725,062
Total current assets		1,369,526			3,508,325

Property and equipment, net		188,895			202,421
Right of use lease asset - operating		1,060,267			1,122,412
Software development costs, net		1,125,368			903,412
Acquired technology, net		6,792,028			-
Customer relationships, net		2,729,920			2,980,412
Forward purchase agreement		5,784,556			5,484,556
Goodwill		1,484,966			1,484,966
Total long-term assets		19,166,000			12,178,179

TOTAL ASSETS	$	20,535,526		$	15,686,504

LIABILITIES AND STOCKHOLDERS’ EQUITY
Accounts payable and accrued expenses	$	4,894,053		$	3,243,338
Operating lease liability, current portion		240,705			241,945
Notes payable, current portion		6,388,603			4,720,454
Related party notes payable		572,127			550,975
Deferred revenue		180,712			119,598
Total current liabilities		12,276,200			8,876,310

Long-term debt, net of current maturities		1,195,432			1,420,137
Operating lease liability, net of current portion		886,014			945,889
Total long-term liabilities		2,081,446			2,366,026

TOTAL LIABILITIES		14,357,646			11,242,336

STOCKHOLDERS’ EQUITY

Preferred Stock par value $0.0001; 40,000,000 shares authorized; Issued and Outstanding: 4,376,709 as of March 31, 2024 and 3,755,209 as of December 31, 2023		438			376
Common Stock par value $0.0001; 100,000,000 shares authorized; Issued and Outstanding: 10,240,398 as of March 31, 2024 and 10,068,477 as of December 31, 2023		1,024			1,007
Additional paid-in-capital		126,386,147			119,481,543
Accumulated deficit		(120,209,729	)		(115,038,758	)
TOTAL STOCKHOLDERS’ EQUITY		6,177,880			4,444,168

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	20,535,526		$	15,686,504

The accompanying notes to the condensed consolidated financial statements

Table of Contents

iCoreConnect Inc.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

	Three Months Ended
	March 31,			March 31,
	2024			2023
	(unaudited)			(unaudited)

Revenue, net	$	2,723,363			1,840,371
Cost of sales		513,097			491,449
Gross profit		2,210,266			1,348,922

Expenses
Selling, general and administrative		4,519,898			2,411,071
Depreciation and amortization		732,553			288,909
Total operating expenses		5,252,451			2,699,980
Loss from operations		(3,042,185	)		(1,351,058	)

Other income (expenses)
Interest expense		(226,467	)		(257,913	)
Finance charges		(1,302,697	)		(80,063	)
Change in fair value of forward purchase agreement		300,000			-
Income taxes		(54,000	)		-
Other expense		(397,621	)		-
Total other expenses		(1,680,785	)		(337,976	)

Net loss		(4,722,970	)		(1,689,034	)

Preferred dividend		(448,000	)		-

Net loss attributable to common stockholders	$	(5,170,970	)	$	(1,689,034	)

Net loss per share available to common stockholders, basic and diluted	$	(0.51	)	$	(0.26	)

Weighted average number of shares, basic and diluted		10,100,426			6,490,738

The accompanying notes to the condensed consolidated financial statements

Table of Contents

iCoreConnect Inc.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT)

FOR THE THREE MONTHS ENDED MARCH 31, 2024 AND 2023 (UNAUDITED)

											Additional					Total Stockholders’
	Common stock						Preferred Stock				Paid In		Accumulated			Equity
	Shares			Amount			Shares		Amount		Capital		Deficit			(Deficit)
Balances at January 1, 2023 (as previously reported)		181,320,528		$	181,321			-	$	-	$	86,192,262	$	(88,875,087	)	$	(2,501,504	)
Retroactive application of reverse capitalization (Note 3)		(175,244,450	)		(180,713	)		-		-		180,713		(10,243,309	)		(10,243,309	)
Balances at January 1, 2023		6,076,078			608			-		-		86,372,975		(99,118,396	)		(12,744,813	)
Stock issued for cash		180,966			18							539,982					540,000
Origination fee in convertible debt agreement												80,063					80,063
Stock issued for conversion of debt		236,502			24							685,309					685,333
Stock compensation expense		5,027			1							272,982					272,983
Net loss														(1,689,034	)		(1,689,034	)
Balance at March 31, 2023		6,498,573		$	651			-	$	-	$	87,951,311	$	(100,807,430	)	$	(12,855,468	)

Balances at January 1, 2024	10,068,477	$	1,007	3,755,209	$	376	$	119,481,543	$	(115,038,758	)	$	4,444,168
Origination fee in convertible debt agreement	85,174		8					181,996					182,004
Stock issued for purchase of Verifi Dental Limited				84,000		8		839,992					840,000
Stock issued for purchase of FeatherPay				480,000		48		4,799,952					4,800,000
Stock issued for the purchase of Teamworx				57,500		6		574,994					575,000
Stock compensation expense	86,747		9					507,670					507,679
Net loss	-		-					-		(5,170,970	)		(5,170,970	)
Balances at March 31, 2024	10,240,398	$	1,024	4,376,709	$	438	$	126,386,147	$	(120,209,729	)	$	6,177,880

The accompanying notes to the condensed consolidated financial statements

Table of Contents

iCoreConnect Inc.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

	Three Months Ended
	March 31,			March 31,
	2024			2023
	(unaudited)			(unaudited)
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(5,170,970	)		(1,689,034	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense		13,526			5,733
Amortization expense		719,028			283,176
Finance fee		182,922			80,063
Change in allowance for doubtful accounts		123,797			35,982
Stock compensation expense		507,670			272,983
Non-cash interest expense		226,466			15,535
Change in fair value of forward purchase agreement		(300,000	)		-
Changes in operating assets and liabilities:
Accounts receivable		(16,822	)		36,449
Prepaid expenses and other current assets		1,005,715			(56,279	)
Right of use asset, net of lease liability		1,030			1,981
Accounts payable and accrued expenses		1,650,714			(192,149	)
Deferred revenue		66,894			53,345
NET CASH USED IN OPERATING ACTIVITIES		(990,030	)		(1,152,215	)

INVESTING ACTIVITIES
Cash portion of consideration paid to acquire assets – Verifi Dental Limited		(370,000	)		-
Cash portion of consideration paid to acquire assets - FeatherPay		(500,000	)		-
Purchase of capital assets		-			(40,769	)
Additions to capitalized software		(334,437	)		(153,346	)
NET CASH USED IN INVESTING ACTIVITIES		(1,204,437	)		(194,115	)

FINANCING ACTIVITES
Net proceeds from debt		1,423,093			2,000,000
Payments on debt		(309,953	)		(586,421	)
Proceeds from issuance of common stock		-			540,000
NET CASH PROVIDED BY FINANCING ACTIVITIES		1,113,140			1,953,579

NET CHANGE IN CASH		(1,081,327	)		607,249
CASH AT BEGINNING OF THE PERIOD		1,219,358			196,153
CASH AT END OF THE PERIOD	$	138,031		$	803,402

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid during the period for interest	$	74,921		$	215,821

The accompanying notes to the condensed consolidated financial statements

Table of Contents

iCoreConnect Inc.

Notes to Condensed Consolidated Financial Statements

March 31, 2024

1. NATURE OF OPERATIONS

iCoreConnect Inc. (formerly known as FG Merger Corp) (collectively with its subsidiary, the “Company”), a Delaware Corporation, is a cloud-based software and technology company focused on increasing workflow productivity and customer profitability through its enterprise platform of applications and services.

Prior to August 25, 2023, the Company was a special purpose acquisition company formed for the purpose of entering into a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. On August 25, 2023 (the “Closing Date”), the Company consummated the business combination contemplated by the Merger Agreement and Plan of Reorganization by and among FG Merger Corp, a special purpose acquisition company incorporated in Delaware (“FGMC”), FG Merger Sub, Inc., a Nevada corporation and wholly owned subsidiary of FGMC (“Merger Sub”), and iCoreConnect Inc., a Nevada corporation(“iCore”), dated as of January 5, 2023 (“Merger Agreement”). Pursuant to the terms of the Merger Agreement, a business combination between FGMC and iCore. was affected through the merger of Merger Sub with and into iCore, with iCore. surviving the merger as a wholly owned subsidiary of FGMC. On the Closing Date, FGMC was renamed “iCoreConnect Inc.” and the previous iCoreConect Inc. was renamed “iCore Midco, Inc.” (“Old iCore”).

Business Combinations

On January 1, 2024 the Company completed the acquisitions for substantial all the assets of (a)Ally Commerce, Inc. dba FeatherPay; (b) Verifi Dental, Limited; and (c) Teamworx LLC which are all accounted for as asset acquisitions. On September 1, 2023, the Company completed the acquisitions for substantially all of the assets of Preferred Dental Development, LLC which was accounted for as an asset acquisition.

Going Concern and Liquidity

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates continuity of operations, realization of assets, and liquidation of liabilities in the normal course of business.

For the three months ended March 31, 2024, the Company generated an operating loss of $3,042,185. In addition, at March 31, 2024, the Company has an accumulated deficit, and net working capital deficit of $120,209,729 and $10,906,674 respectively. The Company’s activities were primarily financed through private placements of equity securities and issuance of debt. The Company intends to raise additional capital through the issuance of debt and/or equity securities to fund its operations. The Company is reliant on future fundraising to finance operations in the near future. Such financings may not be available on terms satisfactory to the Company, if at all. In light of these matters, there is substantial doubt that the Company will be able to continue as a going concern for a period of 12 months from the issuance date of these financial statements.

Currently, management intends to develop an improved healthcare communications system and intends to develop alliances with strategic partners to generate revenues that will sustain the Company. While management believes in the viability of its strategy to increase revenues and in its ability to raise additional funds, there can be no assurances to that effect. Management’s ability to continue as a going concern is ultimately dependent upon its ability to continually increase the Company’s customer base and realize increased revenues from signed contracts. The financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Table of Contents

2. SUMMARY OF SIGNFICANT ACCOUNTING POLICES

Basis of Presentation

The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.

The accompanying unaudited condensed financial statements should be read in conjunction with the Annual Report on Form 10K as filed with the SEC on April 19, 2024 and Form 10-K/A as filed with the SEC on April 29, 2024. The interim results for the three months ended March 31, 2024 are not necessarily indicative of the results to be expected for the year ending December 31, 2024 or for any future periods.

Accounts Receivable and Allowance for Doubtful Accounts

Accounts receivable are customer obligations due under normal trade terms. The Company maintains an allowance for doubtful accounts for estimated losses resulting from the potential inability of certain customers to make required future payments on amounts due. Management determines the adequacy of this allowance by periodically evaluating the aging and past due nature of individual customer accounts receivable balances and considering the customer’s current financial situation as well as the existing industry economic conditions and other relevant factors that would be useful in assessing the risk of collectability. If the future financial condition of the Company’s customers were to deteriorate, resulting in their inability to make specific required payments, additions to the allowance for doubtful accounts may be required. In addition, if the financial condition of customers improves and collections of amounts outstanding commence or are reasonably assured, then the Company may reverse previously established allowances for doubtful accounts. The Company has estimated and recorded an allowance for doubtful accounts of approximately $37,097 at March 31, 2024 and $102,061 December 31, 2023.

Software Development Costs and Acquired Software

The Company accounts for software development costs, including costs to develop software products or the software component of products to be sold to external users. In accordance with ASC 985-730, Computer Software Research and Development, research and planning phase costs are expensed as incurred and development phase costs including direct materials and services, payroll and benefits and interest costs are capitalized.

The Company has determined that technological feasibility for its products to be marketed to external users was reached before the release of those products. As a result, the development costs and related acquisition costs after the establishment of technological feasibility were capitalized as incurred. Capitalized costs for software to be sold to external users and software acquired in a business combination are amortized based on current and projected future revenue for each product with an annual minimum equal to the straight-line amortization over three years.

Long-Lived Assets and Goodwill

The Company accounts for long-lived assets in accordance with the provisions of ASC 360-10-35, Property, Plant and Equipment, Impairment or Disposal of Long-lived Assets. This accounting standard requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. As part of its impairment assessment in 2023 the Company determined that the carrying value of an intangible asset for customer list exceed its fair value and as such recorded an impairment expense in quarter 4 of 2023 in the amount of $105,676. As of March 31, 2024 there was no impairment of Long-lived Assets.

The Company accounts for goodwill and intangible assets in accordance with ASC 350, Intangibles – Goodwill and Other. Goodwill represents the excess of the purchase price of an entity over the estimated fair value of the assets acquired and liabilities assumed. ASC 350 requires that goodwill and other intangibles with indefinite lives be tested for impairment annually or on an interim basis if events or circumstances indicate that the fair value of an asset has decreased below its carrying value. The Company assess goodwill impairment by the amount by which the carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. As of March 31, 2024 and December 31, 2023 there was no impairment of the Company’s Goodwill.

Table of Contents

Revenue Recognition

We have 6 primary sources of revenue as of March 31, 2024 and December 31, 2023:

We have 6 primary sources of revenue

	1.	Electronic Prescription Software
	2.	Insurance Verifications
	3.	ICD-10 Medical Coding Software
	4.	Encrypted and HIPAA Compliant Secure email
	5.	Analytics
	6.	MSaaS software

1) Electronic Prescription software services are provided on an annual subscription basis using the software as a service (‘SaaS’) model with revenue recognized ratably over the contract term.

2). Insurance verification services are provided on an annual subscription basis using SaaS model with revenue recognized ratably over the contract term.

3) ICD-10 Medical Coding services are provided on an annual subscription basis using the software as a SaaS model with revenues recognized ratably over the contract term.

4) Encrypted and HIPAA compliant and secure email services are provided on an annual subscription basis using the SaaS model with revenues recognized ratably over the contract term.

5) Analytics automatically compiles real-time KPI data on an intuitive dashboard which saves time and helps focus the team during the morning huddle. Additionally, the Practice Metrics page provides custom reporting with rich graphics helping management to view revenue, claims, AR, scheduling and more.

6) MSaaS software services are provided on an annual subscription basis using the software as a service (‘SaaS’) model with revenue recognized ratably over the contract term.

The Company accounts for revenue from contracts with customers in accordance with ASU No. 2017-09, Revenue from Contracts with Customers and a series of related accounting standard updates (collectively referred to as “Topic 606”). This guidance sets forth a five-step revenue recognition model which replaced the prior revenue recognition guidance in its entirety and is intended to eliminate numerous industry-specific pieces of revenue recognition guidance and to require more detailed disclosures. The five steps of the revenue recognition model are: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation.

At contract inception, the Company assesses the goods and services promised in the contract with customers and identifies a performance obligation for each. To determine the performance obligation, the Company considers all products and services promised in the contract regardless of whether they are explicitly stated or implied by customary business practices. The timing of satisfaction of the performance obligation is not subject to significant judgment. The Company measures revenue as the amount of consideration expected to be received in exchange for transferring goods and services. Revenue is recognized net of any taxes collected from customers that are subsequently remitted to governmental authorities.

The Company’s customers are acquired through its own salesforce and through the referrals from its many state association marketing partners. The Company primarily generates revenue from multiple software as a service (SaaS) offerings, which typically include subscriptions to its online software solutions. The Company’s secondary source of revenue is professional services and other revenue related to customer onboarding, IT services and equipment sales that often precede a subscription service offering purchased by the customer. Approximately 90% of the Company’s revenue is subscription based with the remainder being professional services and other IT related revenue. The geographic concentration of the Company’s revenue is 100% in North America.

For the three months ended March 31, 2024 and 2022, disaggregated revenues were recurring revenues of $2,595,050 and $1,703,815, respectively and non-recurring revenues of $128,313 and $136,556, respectively.

Table of Contents

Management has determined that it has the following performance obligations related to its products and services: multiple SaaS offerings, which typically include subscriptions to our online software solutions. Revenue from Software as a Service, hardware, service repairs, and support & maintenance are all recognized at a point in time when control of the goods is transferred to the customer, generally occurring upon shipment or delivery dependent upon the terms of the underlying contract, or services is completed. Our customers do not have the right to take possession of the online software solution. Revenue from subscriptions, including additional fees for items such as incremental contacts, is recognized ratably over the subscription period beginning on the date the subscription is made available to customers. Substantially all subscription contracts are one year. We recognize revenue from on-boarding services and equipment as the services are provided. Amounts billed that have not yet met the applicable revenue recognition criteria are recorded as deferred revenue.

For contracts with customers that contain multiple performance obligations, the Company accounts for the promised performance obligations separately as individual performance obligations if they are distinct. In determining whether performance obligations meet the criteria for being distinct, the Company considers several factors, including the degree of interrelation and interdependence between obligations and whether or not the good or service significantly modifies or transforms another good or service in the contract. After identifying the separate performance obligations, the transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. The Company generally determines the standalone selling prices based on the prices charged to customers. Judgment may be used to determine the standalone selling prices for items that are not sold separately, including taking into consideration either historical pricing practices or an adjusted market assessment. Unsatisfied and partially unsatisfied performance obligations as of the end of the reporting period primarily consist of products and services for which customer purchase orders have been accepted and that are in the process of being delivered.

Transaction price is calculated as the selling price less any variable consideration, consisting of rebates and discounts. Discounts provided to customers are known at contract inception. Rebates are calculated on the “expected value” method where the Company (1) estimates the probability of each rebate amount which could be earned by the distributor, (2) multiplies each estimated amount by its assigned probability factor, and (3) calculates a final sum of each of the probability-weighted amounts calculated in step (2). The sum calculated in step (3) is the rebate amount, which along with discounts reduces the amount of revenue recognized.

The Company has elected to account for shipping and handling activities that occur after the customer has obtained control of a good as a fulfillment cost rather than as an additional promised service. As a result, the Company accrues the costs of shipping and handling when the related revenue is recognized. Costs incurred for shipping and handling are included in costs of goods sold on the Consolidated Statements of Operations. Amounts billed to a customer for shipping and handling are reported as revenue on the Consolidated Statements of Operations.

Advertising Costs

Advertising costs are reported in selling, general and administrative expenses and include advertising, marketing and promotional programs and are charged as expenses in the year in which they are incurred. Advertising costs were $208,085 and $125,048 for the three months ended March 31, 2024 and 2023, respectively.

Accounting for Derivative Instruments

The Company accounts for derivative instruments in accordance with ASC 815 “Derivatives and Hedging”, which requires additional disclosures about the Company’s objectives and strategies for using derivative instruments, how the derivative instruments and related hedged items are accounted for, and how the derivative instruments and related hedging items affect the financial statements.

The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risk. Terms of convertible debt and preferred stock instruments are reviewed to determine whether or not they contain embedded derivative instruments that are required under ASC 815 to be accounted for separately from the host contract and recorded on the balance sheet at fair value. The fair value of derivative liabilities, if any, is required to be revalued at each reporting date, with corresponding changes in fair value recorded in current period operating results.

Freestanding warrants issued by the Company in connection with the issuance or sale of debt and equity instruments are considered to be derivative instruments. Pursuant to ASC 815, an evaluation of specifically identified conditions is made to determine whether the fair value of warrants issued is required to be classified as equity or as a derivative liability.

Table of Contents

Financial Instruments With Down Round Features

The Company follows the guidance of FASB ASU 2017-11, “Earnings per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); and Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features. ASU 2017-11 simplifies the accounting for certain financial instruments with down round features, a provision in an equity-linked financial instrument (or embedded feature) that provides a downround adjustment of the current exercise price based on the price of the future equity offerings. The standard requires companies to disregard the down round feature when assessing whether the instrument is indexed to its own stock, for the purposes of determining liability of equity classification. Companies that provide earning per share (“EPS”) data will adjust their diluted EPS calculation for the effect of the feature when triggered (i.e. when the exercise price of the related equity-linked financial instrument is adjusted downward because of the down round feature) and will also recognize the effect of the trigger within equity.

Income Taxes

The Company follows the asset and liability approach to accounting for income taxes. Under this method, deferred tax assets and liabilities are measured based on differences between the financial reporting and tax bases of assets and liabilities measured using enacted tax rates and laws that are expected to be in effect when differences are expected to reverse. Valuation allowances are established when it is necessary to reduce deferred income tax assets to the amount, if any, expected to be realized in future years.

ASC 740, Accounting for Income taxes (“ASC 740”), requires that deferred tax assets be evaluated for future realization and reduced by a valuation allowance to the extent we believe a portion more likely than not will not be realized. We consider many factors when assessing the likelihood of future realization of our deferred tax assets, including our recent cumulative loss experience and expectations of future taxable income by taxing jurisdictions, the carry forwarding periods available to us for tax reporting purposes and other relevant factors.

The Company has not recognized a liability for uncertain tax positions. A reconciliation of the beginning and ending amount of unrecognized tax benefits or penalties has not been provided since there has been no unrecognized benefit or penalty. If there were an unrecognized tax benefit or penalty, the Company would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. The Company files U.S. Federal income tax returns and various returns in state jurisdictions. The Company’s open tax years subject to examination by the Internal Revenue Service and the state Departments of Revenue generally remain open for three years from the date of filing.

Net Loss Per Share

Basic net loss per share is computed by dividing net loss by the weighted average number of shares of Common Stock outstanding for the period. Diluted net loss per share reflects the potential dilution of securities by adding other Common Stock equivalents, including stock options, shares issuable on exercise of warrants, convertible preferred stock and convertible notes in the weighted average number of common shares outstanding for a period, if dilutive. Common stock equivalents that are anti-dilutive were excluded from the computation of diluted earnings per share which consisted of all outstanding common stock options and warrants.

Table of Contents

Beneficial Conversion Features and Warrants

The Company evaluates the conversion feature of convertible debt instruments to determine whether the conversion feature was beneficial as described in ASC 470-30, Debt with Conversion and Other Options. The Company records a beneficial conversion feature (“BCF”) related to the issuance of convertible debt that has conversion features at fixed or adjustable rates that are in-the-money when issued and records the relative fair value of any warrants issued with those instruments. The BCF for the convertible instruments is recognized and measured by allocating a portion of the proceeds to the warrants and as a reduction to the carrying amount of the convertible instrument equal to the intrinsic value of the conversion features, both of which are credited to additional paid-in capital. The Company calculates the fair value of warrants with the convertible instruments using the Black-Scholes valuation model.

Under these guidelines, the Company first allocates the value of the proceeds received from a convertible debt transaction between the convertible debt instrument and any other detachable instruments included in the transaction (such as warrants) on a relative fair value basis. A BCF is then measured as the intrinsic value of the conversion option at the commitment date, representing the difference between the effective conversion price and the Company’s stock price on the commitment date multiplied by the number of shares into which the debt instrument is convertible. The allocated value of the BCF and warrants are recorded as a debt discount and accreted over the expected term of the convertible debt as interest expense. If the intrinsic value of the BCF is greater than the proceeds allocated to the convertible debt instrument, the amount of the discount assigned to the BCF is limited to the amount of the proceeds allocated to the convertible debt instrument.

Leases

The Company adopted ASU No. 2016-02, Leases and a series of related Accounting Standards Updates that followed (collectively referred to as “Topic 842”). Topic 842 requires organizations to recognize right-of-use (“ROU”) lease assets and lease liabilities on the balance sheet and to disclose key information about leasing arrangements. The classification criteria for distinguishing between finance leases and operating leases are substantially similar to the classification criteria for distinguishing between capital leases and operating leases in the previous lease guidance. The FASB retained the distinction between finance leases and operating leases, leaving the effect of leases in the statement of comprehensive income and the statement of cash flows largely unchanged from previous U.S. GAAP. The Company utilized the transition method allowed under ASU 2018-11 in which an entity initially applies the new lease standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption, if any.

Table of Contents

The Company determines, at contract inception, whether or not an arrangement contains a lease and evaluates the contract for classification as an operating or finance lease. For all leases, ROU assets and lease liabilities are recognized based on the present value of lease payments, including annual rent increases, over the lease term at commencement date. If the Company’s lease does not provide an implicit rate in the contract, the Company uses its incremental, secured borrowing rate based on lease term information available as of the adoption date or lease commencement date in determining the present value of lease payments. Any renewal periods are considered in the analysis of each lease to the extent that the Company considers them to be reasonably certain of being exercised.

Business Combinations

The Company applies the principles provided in the Financial Accounting Standards Board (FASB) Accounting Standards Codification (“ASC”) 805, Business Combinations, to determine whether an acquisition involves an asset or a business. In determining whether an acquisition should be accounted for as a business combination or asset acquisition, The Company first determines whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets. If this is the case, the single identifiable asset or the group of similar assets is accounted for as an asset acquisition. If this is not the case, The Company then further evaluate whether the single identifiable asset or group of similar identifiable assets and activities includes, at a minimum, an input and a substantive process that together significantly contribute to the ability to create outputs. If so, the transaction is accounted for as a business combination.

The Company accounts for business combinations using the acquisition method of accounting which requires that (i) identifiable assets acquired (including identifiable intangible assets) and liabilities assumed generally be measured and recognized at estimated fair value as of the acquisition date and (ii) the excess of the purchase price over the net estimated fair value of identifiable assets acquired and liabilities assumed be recognized as goodwill, which is not amortized for accounting purposes but is subject to testing for impairment at least annually.

The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets. Goodwill is not recognized in an asset acquisition with any consideration in excess of net assets acquired allocated to acquired assets on a relative estimated fair value basis. Transaction costs are expensed in a business combination and transaction costs directly attributable to an asset acquisition are considered a component of the cost of the asset acquisition.

Allowance for Credit Losses

On January 1, 2023, the Company adopted ASU 2016-13 Financial Instruments —Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (ASC 326). This standard replaced the incurred loss methodology with an expected loss methodology that is referred to as the current expected credit loss (“CECL”) methodology. CECL requires an estimate of credit losses for the remaining estimated life of the financial asset using historical experience, current conditions, and reasonable and supportable forecasts and generally applies to financial assets measured at amortized cost, including loan receivables and held-to-maturity debt securities, and some off-balance sheet credit exposures such as unfunded commitments to extend credit. Financial assets measured at amortized cost will be presented at the net amount expected to be collected.

The Company completed its assessment on the adoption date of the new standard and did not adjust the opening balance of retained earnings relating to its trade receivables. The Company writes off receivables once it is determined that they are no longer collectible, as local laws allow.

Recently Issued Accounting Pronouncements

Adopted

In November 2023, the FASB issued ASU 2023-07, “Segment Reporting - Improving Reportable Segment Disclosures (Topic 280).” The standard is intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant expenses. The standard requires disclosure to include significant segment expenses that are regularly provided to the CODM, a description of other segment items by reportable segment, and any additional measures of a segment’s profit or loss used by the CODM when deciding how to allocate resources. The standard also requires all annual disclosures currently required by ASC Topic 280 to be included in interim periods. This standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted and requires retrospective application to all prior periods presented in the financial statements. The Company completed its assessment of the new standard and determined that the standard did not apply as the Company currently only has one reportable segment.

Not Yet Adopted

In October 2023, the FASB issued Accounting Standards Update (“ASU”) 2023-06, “Disclosure Improvements – Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative.” This standard affects a wide variety of Topics in the Codification. The effective date for each amendment will be the date on which the SEC’s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective. Early adoption is prohibited. The Company does not expect the adoption of this standard to have a material impact on the Company’s consolidated financial statements and related disclosures.

In December 2023, the FASB issued ASU 2023-09, “Improvements to Income Tax Disclosures,” a final standard on improvements to income tax disclosures, The standard requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. The standard is effective for fiscal years beginning after December 15, 2024, with early adoption permitted and should be applied prospectively. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures.

Table of Contents

3. BUSINESS COMBINATION AND RECAPITALIZATION

On August 25, 2023, Old iCore and FGMC consummated the Business Combination, with Old iCore surviving as a wholly owned subsidiary of FGMC. As part of the Business Combination, FGMC changed its name to iCoreConnect Inc. Upon the closing of the Business Combination (the “Closing”), the Company’s certificate of incorporation provided for, among other things, a total number of authorized shares of capital stock of 140,000,000 shares, of which 40,000,000 shares were designated Series A preferred stock, $0.0001 par value per share and 100,000,000 were designated common stock, $0.0001 par value per share.

The Business Combination is accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, FGMC is treated as the “acquired” company and Old iCore is treated as the acquirer for financial reporting purposes. Accordingly, for accounting purposes, the Business Combination was treated as the equivalent of Old iCore issuing stock for the net assets of FGMC, accompanied by a recapitalization. The net assets of FGMC are stated at historical cost, with no goodwill or intangible assets recorded.

Upon the consummation of the Business Combination, each issued and outstanding share of Old iCore Common Stock was canceled and converted into Company Common Stock based upon the Exchange Ratio (as defined in the Merger Agreement). The shares and corresponding capital amounts and loss per share related to Old iCore Common Stock prior to the Business Combination have been retroactively restated to reflect the Exchange Ratio. All non-redeemed shares of FGMC common stock were converted into new iCoreConnect Inc. Series A preferred stock (the “Preferred Stock”) on a one for one basis.

Unvested outstanding stock options to purchase shares of Old iCore Common Stock (“Old iCore Options”) granted under the iCoreConnect Inc 2016 Stock Incentive Plan (“2016 Plan”) converted into stock options for shares of Company Common Stock upon the same terms and conditions that were in effect with respect to such stock options immediately prior to the Business Combination, after giving effect to the Exchange Ratio (the “Exchanged Options”). Old iCore Options that were vested at the time of the merger converted into shares of Company Common Stock upon the same terms and conditions that were in effect with respect to such options immediately prior to the Business Combination, after giving effect to the Exchange Ratio.

Outstanding warrants to purchase shares of Old iCore Common Stock (“Old iCore warrants”) issued and outstanding converted into shares of Company Common Stock upon the same terms and conditions that were in effect with respect to such warrants immediately prior to the Business Combination, after giving effect to the Exchange Ratio.

The following table details the number of shares of Company Common Stock issued immediately following the consummation of the Business Combination:

	Common Stock			Preferred Stock

Common stock of FGMC outstanding prior to business combination		8,050,000			-
Less: Redemptions of FGMC common stock		(6,460,059	)		-
Common stock held by former FGMC shareholders		1,589,941			-
FGMC sponsor shares		1,692,374			-
Underwriter shares		40,250			-
Sponsor shares transferred for services		2,000			-
Sponsor shares transferred for non-redemption		373,126			-
Shares issued related to extension note		84,500			-
Total FGMC common shares outstanding prior to conversion to preferred stock		3,782,191			-
Conversion of existing FGMC common stockholders to new preferred stock		(3,782,191	)		3,782,191
Shares issued to Old iCore stockholders for purchase consideration		8,095,706			-
Total		8,095,706			3,782,191

Table of Contents

The following table reconciles the elements of the Business Combination to the Company’s condensed consolidated statement of changes in stockholders’ equity (deficit):

	Amount
Cash - FGMC trust (net of redemptions)	$	17,002,897
Cash transferred to Forward Purchase Agreement		(12,569,810	)
Gross proceeds		4,433,087
Less: FGMC and Old iCore transaction costs paid		(4,433,087	)
Effect of Business Combination, net of redemptions and transaction costs	$	-

All existing FGMC warrants were converted into Preferred Stock warrants with the same terms and conditions:

Holder	Number of Warrants		Strike Price
Underwriter		600,000	$	2.00
Sponsor and Investors		10,122,313	$	11.50
Sponsor		1,000,000	$	15.00

4. INTANGIBLE ASSETS AND GOODWILL

The following table sets forth the gross carrying amounts and accumulated amortization of the Company’s intangible assets as of March 31, 2024 and December 31, 2023:

	Gross Carrying Amount		Impairment			Accumulated Amortization			Net Carrying Amount
Definite-lived intangible assets:
Capitalized software	$	3,741,511	$	-		$	(2,838,099	)	$	903,412
Customer relationships		5,272,578		(105,676	)		(2,186,490	)		2,980,412
Acquired technology		1,527,186		-			(1,527,186	)		-
Total definite-lived intangible assets at December 31, 2023		10,541,275		(105,676	)		(6,551,775	)		3,883,824

Capitalized software		4,075,948		-			(2,950,580	)		1,125,368
Customer relationships		5,166,903		-			(2,436,983	)		2,729,920
Acquired technology		7,148,083		-			(356,055	)		6,792,028
Total definite-lived intangible assets at March 31, 2024	$	16,390,934		-		$	(5,743,618	)	$	10,647,316

In January 2024, the Company purchased Acquired Technology in the amount of $7,148,083. In September 2023, the Company purchased customer relationships in the amount of $1,559,145. The Company also added $334,437 in capitalized software for the three months ended March 31, 2024. Amortization expense of intangible assets was $719,028 and $283,176 for the three months ended March 31, 2024 and 2023, respectively. The Company’s amortization is based on no residual value using the straight-line amortization method as it best represents the benefit of the intangible assets.

The following table sets forth the changes in the carrying amount of goodwill for the three months ended March 31, 2024 and year ended December 2023:

	Total
Balance at December 31, 2023	$	1,484,966
2024 acquisitions		-
Balance at March 31, 2024	$	1,484,966

5. FORWARD PURCHASE AGREEMENT

On August 14, 2023, the Company entered into Prepaid Forward Purchase Agreement (the “FPA”) with Old iCore and RiverNorth SPAC Arbitrage Fund, L.P., a Delaware limited partnership (the “Purchaser”).

In accordance with the FPA and subject to the terms and conditions set forth therein, the Purchaser purchased the lesser of (a) 1.5 million shares of FGMC Common Stock and (b) such number of shares of FGMC Common Stock as shall, following the Business Combination, not exceed 9.9% of the total number of shares of FGMC Common Stock to be outstanding (such shares to be purchased, the “Forward Purchase Shares”) from public shareholders for a price no greater than the redemption price per share as is indicated in FGMC’s most recently filed periodic report (the “Prepaid Forward Purchase Price”).

In accordance with the terms of the Business Combination, upon the consummation of the Business Combination, each Forward Purchase Share automatically converted into one share of Preferred Stock (including the shares of the Company’s Common Stock underlying the Preferred Stock, the “Purchased Shares”).

Table of Contents

Upon the Business Combination closing, 100,000 Purchased Shares were deemed to be “Commitment Shares” and the remaining Purchased Shares were deemed to be “Prepaid Forward Purchase Shares”.

Upon the closing of the Business Combination FGMC caused Purchaser to be paid directly out of the funds held in FGMC’s trust account, a cash amount (the “Prepayment Amount”) equal to the number of Purchased Shares multiplied by the amount paid to redeeming stockholders in connection with the Business Combination (the “Redemption Price”). The Redemption Price was $[10.69].

Upon the sale of the Prepaid Forward Purchase Shares (or underlying FGMC Common Stock) by the Purchaser, the Purchaser will remit the Reference Price (as defined below) per share to FGMC. On the earlier to occur of:

	·	the occurrence of a “Registration Failure” (as defined in the FPA), and

	·	the date that is twelve months after the closing of the Business Combination (the “Maturity Date”), then, for any Common Stock underlying the Prepaid Forward Purchase Shares not sold by the Purchaser, the Purchaser shall, on the 25th trading day after the Maturity Date (the “Payment Date”), pay the Company an amount equal to (i) the number of Prepaid Forward Purchase Shares that the Purchaser held on the Maturity Date, multiplied by (ii) the lowest daily volume weighted average price per share of FGMC Common Stock during the twenty trading days beginning on the day after the Maturity Date less $0.15.

Between the Maturity Date and the Payment Date, the Purchaser may not sell more than a number of Prepaid Forward Purchase Shares per day equal to the greater of (i) 5% of the Purchased Shares owned by the Purchaser at the Maturity Date and (ii) 10% of the daily trading volume on such date.

The Purchaser has agreed that until the Maturity Date, the Common Stock underlying the Prepaid Forward Purchase Shares may not be sold for a price less than the Reference Price. The “Reference Price” will initially equal the Redemption Price and will be reduced (but never increased) each month commencing on the first day of the month starting 30 days after the Business Combination closing to the volume weighted average price of the FGMC Common Stock for the preceding 10 trading days, but in no event less than $10.00 per share (the “Floor”) unless in the Company’s sole discretion, the Floor is lowered. Any reduction of the Floor shall be accomplished through a written notice from the Company to Purchaser.

The FPA provides for certain registration rights. In particular, FGMC is required to, within 30 calendar days following written request by Purchaser, file with the SEC a registration statement registering the resale of all shares held by Purchaser and have such registration statement declared effective as soon as practicable after the filing thereof.

6. NOTES PAYABLE

		March 31,			December 31,
		2024			2023
(2)	Note bearing interest at 18% due October 1, 2026		25,325			27,540
(3)	Secured Promissory Note bearing interest at 17.5% due February 28, 2026		1,753,761			1,988,793
(4)	Promissory Note bearing interest at 12%, due October 31, 2023		-			38,609
(5)	Convertible Note bearing interest at 12% due May 13, 2024		369,560			388,380
(6)	Convertible Note bearing interest at 12%, due October 31, 2024		564,513			569,391
(6)	Convertible Note bearing interest at 12%, due December 18, 2024		572,407			574,961
(7)	Convertible Note bearing interest at 12%, due December 19, 2024		79,813			80,722
(8)	Convertible Note bearing interest at 12%, due December 19, 2024		79,813			80,509
(5)	Convertible Note bearing interest at 12%, due December 28, 2024		125,092			114,781
(1)	Convertible Note bearing interest at 12%, due June 1, 2024		527,603			473,743
(9)	Promissory Note bearing interest at 15%, due December 26, 2024		2,074,795			2,000,000
(21)	Promissory Note bearing interest at 12%, due May 3, 2024		127,425			-
(11)	Convertible Note bearing interest at 12%, due February 1, 2025		57,629			-
(12)	Convertible Note bearing interest at 12%, due February 1, 2025		5,763			-
(13)	Convertible Note bearing interest at 16%, due February 26, 2025		404,225			-
(13)	Convertible Note bearing interest at 16%, due February 26, 2025		1,280,047			-
	Total notes payable		8,047,771			6,337,429
	Less: Unamortized debt discounts		(104,167	)		-
	Less: unamortized financing costs		(359,569	)		(196,837	)
	Total notes payable, net of financing costs		7,584,035			6,140,592
	Less current maturities		(6,388,603	)		(4,720,455	)
	Total Long-Term Debt	$	1,195,432		$	1,420,137

1.	On February 9, 2024, the Company issued a convertible note entered into a securities purchase agreement with an investor with an effective date of December 29, 2023, pursuant to which the Company in principal amount of $473,743 in exchange for the conversion of a payable in the amount of $473,743. The maturity of the convertible note is June 1, 2024 and carries an interest rate of 12% per annum and is convertible into Company common stock at a conversion rate equal to 100% of the closing price of the Company’s common stock on December 29, 2023, provided such conversion right is subject to approval of the transaction by the Company’s shareholders.

2.	In November 2021, the Company signed a $40,071 equipment finance agreement with a maturity date 60 months after issuance from a third-party financing company. Payments of principal and interest of $791 are due monthly.

3.	On February 28, 2022, the Company signed a $2,000,000 secured promissory note with a maturity date 48 months after issuance and received in exchange $1,970,000 net of fees. An Interest charge of 17.5% per annum shall accrue, with interest only payments being made for the first six months after which both interest and principal will be due. The Company has right of prepayment subject to certain minimum interest payments being made. The Prepayment Fee shall be (i) equal to 6 months’ interest that would have accrued with regard to the prepaid principal, if prepaid prior to the 2nd anniversary of the date of the Initial Advance or Subsequent Advance, as applicable, and (ii) equal to 3 months’ interest that would have accrued with regard to the prepaid principal, if prepaid on or after the 2nd anniversary and prior to the 3rd anniversary of the date of the Initial Advance or Subsequent Advance, as applicable. Additionally, the Company has the following covenant requirements; maintaining a minimum cash balance of $150,000 in its combined bank accounts as well as entering into a Deposit Account Control Agreement; monthly financial reporting requirements and certifications; obtaining other indebtedness without consent; merge, consolidate or transfer assets; pledge assets as collateral; or guarantee without consent of the Lender. On February 12, 2024, the Company entered into a Forbearance Agreement with an effective date of December 31, 2024 whereby the Company agreed to make $300,000 payment to cure certain defaults under the original Loan Agreement. In addition, the Company agreed to increase the default rate of interest in the Loan Agreement, report certain financial and cash metrics on a weekly basis, budgetary updates as well as pay down of balance of 10% of all financing raised over $500,000, in exchange for interest only payments until July 2024 and waiver of all covenants

Table of Contents

4.		In September 2023 the Company entered into a sixty-day Promissory Note (“Note”) in the amount of $1,200,000 related to its purchase of the assets of Preferred Dental Development LLC. The Note carries an interest of 12% per annum and is subordinated to the Company’s senior lenders. The principal balance of the note was fully repaid in December 31, 2023 with only the interest portion of $38,609 outstanding as of December 31, 2023. The note was fully repaid in January 2024. The promissory note was subordinated to the Company’s senior lenders.

5.		In October 2023, the Company entered into a promissory note for $350,000. The maturity of the Promissory Note is May 13, 2024 and carries an interest rate of 12% per annum and is initially convertible into Company common stock at a conversion rate of $1.85 per share. In conjunction with the Promissory Note, the Company also issued a five-year warrant to purchase 24,500 shares of Company common stock with an exercise price of $2.04. The value of the warrants of 13,498 as determined by a Black-Scholes calculation is separated from the value of the note and expensed equally over the term of the note as a financing fee. On December 28, 2023, the Company entered into a securities purchase agreement with the existing investor, pursuant to which the Company issued the investor a convertible note in principal amount of $100,000. The maturity of the convertible note is December 28, 2024 and carries an interest rate of 12% per annum and is initially convertible into Company common stock at a conversion rate equal to 120% of the closing price of the Company’s common stock on the date of issuance which was $1.31 or $1.57 for the share price of conversion. In December 2023, the Company entered into an amendment with holder of an Amendment to Convertible Promissory Notes issued in October 2023 whereby the holder of the Note agreed that the Note would not be convertible into shares of Company Common Stock unless and until the Company’s shareholders approve such conversion per NASDAQ Listing Rule 5635(d). The Company and the Note holder also entered into amendments to the warrants to purchase common stock issued in connection with the issuance of the Note, pursuant to which the holder of the Warrants agreed that the Warrants would not become exercisable unless and until the Company’s shareholders approve the exercise of the Warrants pursuant to NASDAQ Listing Rule 5635(d). The promissory notes are subordinated to the Company’s senior lender.

6.		In October 2023, the Company entered into a securities purchase agreement with an investor, pursuant to which the Company issued the investor a Convertible Promissory Note in principal amount of $500,000. The maturity of the Convertible Promissory Note is October 31, 2024 and carries an interest rate of 12% per annum and is initially convertible into Company common stock at a conversion rate equal to 120% of the closing price of the Company’s common stock on the date of issuance which was $1.58 or $1.90. In December 2023, the Company entered into a securities purchase agreement with the existing investor, pursuant to which the Company issued the investor a convertible note in principal amount of $500,000. The maturity of the convertible note is December 18, 2024 and carries an interest rate of 12% per annum and is initially convertible into Company common stock at a conversion rate equal to 120% of the closing price of the Company’s common stock on the date of issuance which was $2.31 or $2.77 for the share price of conversion. The promissory notes are subordinated to the Company’s senior lender.

7.		In December 2023, the Company entered into a securities purchase agreement pursuant to which the Company issued a convertible note in principal amount of $70,000. The maturity of the convertible note is December 19, 2024 and carries an interest rate of 12% per annum and is initially convertible into Company common stock at a conversion rate equal to 120% of the closing price of the Company’s common stock on the date of issuance which was $1.69 or $2.03 for the share price of conversion. The promissory notes are subordinated to the Company’s senior lender.

Table of Contents

8.		In December 2023, the Company entered into a securities purchase agreement pursuant to which the Company issued a convertible note in principal amount of $70,000. The maturity of the convertible note is December 19, 2024 and carries an interest rate of 12% per annum and is initially convertible into Company common stock at a conversion rate equal to 120% of the closing price of the Company’s common stock on the date of issuance which was $1.69 or $2.03 for the share price of conversion. The promissory notes are subordinated to the Company’s senior lender.

9.		In December 2023, the Company issued a subordinated note to a service provider in principal amount of $2,000,000 in exchange for conversion of an account payable in the amount of $2,000,000. The maturity of the subordinated note is December 26, 2024 and carries an interest rate of 15% per annum and is to be paid in interest only installments for three months followed with a ballon payment in month four and then a combination of principal and interest payments for the remaining term. The note is secured by the assets of the Company and is junior to the security interest of the Company’s senior lender. As part of the note payable the Company agreed to purchase investor relation consulting services totaling $200,000 payable in quarterly installments beginning in January 2024.

10.	On January 1, 2024 the Company entered into a promissory note with Teamworx for $125,000 due January 31, 2024 with no interest. On February 1, 2024, the note was extended to February 29, 2024 with 12% with principal and interest due at maturity. On March 1, 204 the note was extended again to April 30, 2024 with principal and interest due at maturity. This note was further extended to May 6, 2024 under the same terms.

11.		On February 1, 2024, the Company entered into a securities purchase agreement with an investor, pursuant to which the Company issued the investor a convertible note in principal amount of $50,000 in exchange for $50,000. The maturity of the convertible note is February 1, 2025 and carries an interest rate of 12% per annum and is initially convertible into Company common stock at a conversion rate equal to 120% of the closing price of the Company’s common stock on the date of issuance. The convertible note is being sold and issued without registration under the Securities Act of 1933, as amended (the “Securities Act”), in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D promulgated under the Securities Act as sales to an accredited investor, and in reliance on similar exemptions under applicable state laws.

12.		On February 1, 2024, the Company entered into a securities purchase agreement with an investor, pursuant to which the Company issued the investor a convertible note in principal amount of $5,000 in exchange for $5,000. The maturity of the convertible note is February 1, 2025 and carries an interest rate of 12% per annum and is initially convertible into Company common stock at a conversion rate equal to 120% of the closing price of the Company’s common stock on the date of issuance. The convertible note is being sold and issued without registration under the Securities Act of 1933, as amended (the “Securities Act”), in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D promulgated under the Securities Act as sales to an accredited investor, and in reliance on similar exemptions under applicable state laws.

13.		On February 26, 2024, The Company executed a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (the “Investors”). Pursuant to the terms and conditions of the Purchase Agreement, the Investors agreed to purchase from the Company unsecured convertible notes in the aggregate principal amount of up to $2,375,000. The Purchase Agreement contemplates funding of the investment across two tranches. At the first closing (the “Initial Closing”) an aggregate principal amount of $1,375,000 will be issued upon the satisfaction of certain customary closing conditions in exchange for aggregate gross proceeds of $1,250,000, representing an original issue discount of 10%. On such date (the “Initial Closing Date”), the Company will also issue the Investors 85,174 shares of Company common stock (the “Commitment Shares”). Subject to satisfying the conditions discussed below, the Company has the right under the Purchase Agreement, but not the obligation, to require that the Investors purchase additional Notes at one additional closing. Upon notice, the Company may require that the Investors purchase an additional aggregate principal amount of $1,100,000 of Notes, in exchange for aggregate gross proceeds of $1,000,000, if, among other items, (i) the Registration Statement (as described below) is effective; and (ii) the Shareholder Approval (as described below) has been obtained. The Notes will mature 12 months from their respective issuance date (the “Maturity Date”), unless earlier converted. Commencing on the six-month anniversary of the issue date, the Company will be required to make monthly amortization payments pursuant to the Note of approximately 1/6th of the principal amount of the Note per month (the “Amortization Payments”). The Notes will be the Company’s unsecured obligations and equal in right of payment with all of our other indebtedness and other indebtedness of any of our subsidiaries. The Notes were issued with an original issue discount of 10.0% per annum, and will not accrue additional interest during the term; provided that the interest rate of the Notes will automatically increase to 16% per annum (the “Default Rate”) upon the occurrence and continuance of an event of default. Each holder of Notes may convert all, or any part, of the outstanding Notes, at any time at such holder’s option, into shares of the Company’s common stock at an initial “Conversion Price” of $1.848 per share, which is subject to proportional adjustment upon the occurrence of any stock split, stock dividend, stock combination and/or similar transactions. With limited exceptions, if the Company at any time while a Note is outstanding, issues any common stock or securities entitling any person or entity to acquire shares of common stock (upon conversion, exercise or otherwise), at an effective price per share less than the Conversion Price then the Conversion Price shall be reduced to the same price as the new investment. A holder shall not have the right to convert any portion of a Note to the extent that, after giving effect to such conversion, the holder (together with certain related parties) would beneficially own in excess of 4.99%, or the “Maximum Percentage”, of shares of the Company’s common stock outstanding immediately after giving effect to such conversion. If the Company fails to make any Amortization Payments when due, then each holder may alternatively elect to convert all or any portion of such holder’s Notes at a conversion price equal to the lesser of (i) the Conversion Price, and (ii) 90% of the lowest VWAP of the common stock during the five (5) consecutive trading days immediately prior to such conversion. The Company received a waiver for untimely filing of its regulatory reporting requirements from the lender.

Table of Contents

7. RELATED PARTY TRANSACTIONS

		March 31,			December 31,
		2023			2023
(2)	Related Party Promissory Note bearing interest at 18%, due December 31, 2023	$	-		$	249,855
(1)	Related Party Promissory Note bearing interest at 12%, due December 31, 2023		-			225,797
(1)	Related Party Convertible Promissory Note bearing interest at 12%, due May 26, 2024		113,708			96,753
(2)	Related Party Promissory Note bearing interest at 20%, due April 30, 2024		280,753			-
(1)	Related Party Convertible Promissory Note bearing interest at 12%, due April 30, 2024		223,975			-
	Total notes payable		618,436			572,405
	Less: Unamortized debt discounts		-			-
	Less: unamortized financing costs		(46,309	)		(21,431	)
	Total notes payable, net of financing costs		572,127			550,974
	Less current maturities		(572,127	)		(550,974	)
	Total Long-Term Debt	$	-		$	-

1.	In October 2023 the Company entered into two separate new notes with a related party; (a) $200,000 Promissory Note with 12% interest per annum which shall be paid on the maturity date which is December 31, 2023. In conjunction with the issuance of the Promissory Note, the Company also issued the investor a five-year warrant (the “Warrant”) to purchase 14,000 shares of Company common stock with an exercise price of $2.16 per share, which was 120% of the closing price of the Company’s common stock on the date of issuance; (b) the Company issued the investor a convertible promissory note in principal amount of $94,685.91 The maturity of the Convertible Promissory Note is May 26, 2024 and carries an interest rate of 12% per annum and is initially convertible into Company common stock at a conversion rate of $1.80 per share, which was the closing price of the Company’s common stock on the date of issuance. In conjunction with the Convertible Promissory Note, the Company also issued the investor 6,629 shares of Company common stock and a five-year warrant to purchase 6,629 shares of Company common stock with an exercise price of $2.15 per share, which was 120% of the closing price of the Company’s common stock on the date of issuance. In December 2023, the Company entered into an amendment with holder of an Amendment to Convertible Promissory Notes issued in October 2023 whereby the holder of the Note agreed that the Note would not be convertible into shares of Company Common Stock unless and until the Company’s shareholders approve such conversion per NASDAQ Listing Rule 5635(d). The Company and the Note holder also entered into amendments to the warrants to purchase common stock issued in connection with the issuance of the Note, pursuant to which the holder of the Warrants agreed that the Warrants would not become exercisable unless and until the Company’s shareholders approve the exercise of the Warrants pursuant to NASDAQ Listing Rule 5635(d). On April 8, 2024 with an effective date of January 1, 2024, the Company entered into a securities purchase agreement with a related party pursuant to which the Company issued the related party a convertible note in the principal amount of $200,000 in exchange for $200,000. The maturity of the convertible note is April 30, 2024 and carries an interest rate of 12% per annum and is initially convertible into Company common stock at a conversion rate equal to 120% of the closing price of the Company’s common stock on the date of issuance. In conjunction with the April 8, 2024 Note, we issued the investor a five-year warrant to purchase 30,000 shares of our common stock with an exercise price of $1.50. Accrued and unpaid interest as of March 31, 2024 was $5,976 and unamortized financing costs were $17,998.

2.	In June 2023 the Company entered into a promissory note with an entity controlled by its Chief Executive Officer, a related party. The Note is for $250,000 with $50,000 paid to the Holder on issuance for net proceeds of $200,000 and matures on December 31, 2023. The Note carries an interest of 15% per annum as interest is payable monthly in arrears with principal due at maturity. There is no penalty for early payoff. If an event of default occurs, the Note along with any outstanding and accrued interest is convertible into the Company’s Common Stock at $7.45 at the sole discretion of the issuer. On April 8, 2024 with an effective date of January 1, 2024, the Company entered into a securities purchase agreement with a related party pursuant to which the Company issued the related party a promissory note in the principal amount of $260,000 in exchange for $260,000. The maturity of the promissory note is April 30, 2024 and carries an interest rate of 20% per annum. In conjunction with the April 8, 2024 Note, we issued the investor a five-year warrant to purchase 39,000 shares of our common stock with an exercise price of $1.50. The promissory note is subordinated to the Company’s senior lender. Accrued and unpaid interest as of March 31, 2024 was $6,474 and unamortized financing costs were $ $14,279.

8. COMMON AND PREFERRED STOCK

Common Stock

The Company is authorized to issue up to 100,000,000 shares of Company Common Stock, par value $0.0001 per shares.

During the three months ended March 31, 2024 the Company issued 85,174 shares of common stock on the issuance of convertible debt and 86,747 shares of common stock related to stock based compensation.

Table of Contents

Preferred Stock

The Company is authorized to issue up to 40,000,000 shares of Company Series A Preferred Stock, par value $0.0001 per shares. The Preferred Stock have the rights, preferences, powers, privileges and restrictions, qualifications and limitations including but not limited to:

	•	The conversion price (“Conversion Price”) for the Preferred Stock is initially $10.00 per share; provided that the Conversion Price shall be reset to the lesser of $10.00 or 20% above the simple average of the volume weighted average price on the 20 trading days following 12 months after August 25, 2023; provided further that such Conversion Price shall be no greater than $10.00 and no less than $2.00 and subject to appropriate and customary adjustment.

	•	The holders of Preferred Stock shall not be entitled to vote on any matters submitted to the stockholders of the Company.

	•	From and after the date of the issuance of any shares of Preferred Stock, dividends shall accrue at the rate per annum of 12% of the original issue price for each share of Preferred Stock, prior and in preference to any declaration or payment of any other dividend (subject to appropriate adjustments).

	•	Dividends shall accrue from day to day and shall be cumulative and shall be payable within fifteen (15) business days after the end of the Company’s second quarter, which is June 30, commencing with the quarter ending June 30, 2024 to each holder of Preferred Stock as of such date.

	•	From the Closing of the Business Combination until the second anniversary of the date of the original issuance of the Preferred Stock, the Company may, at its option, pay all or part of the accruing dividends on the Preferred Stock by issuing and delivering additional shares of Preferred Stock to the holders thereof.

	•	The Company shall not declare, pay or set aside any dividends on shares of any other class or series of capital stock of the Company, unless the holders of the iCoreConnect Preferred Stock then outstanding shall first receive dividends due and owing on each outstanding share of iCoreConnect Preferred Stock.

	•	In the event of any liquidation, dissolution or winding up of the Company, the holders of shares of Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to its stockholders an amount per share equal to the greater of (i) one times the applicable original issue price, plus any accrued and unpaid dividends, and (ii) such amount as would have been payable had all shares of Preferred Stock been converted into the Company’s Common Stock pursuant to the following paragraph immediately prior to such liquidation, dissolution or winding up, before any payment shall be made to the holders of the Company’s Common Stock.

	•	Each share of Preferred Stock shall be convertible, at the option of the holder thereof, at any time and from time to time, and without the payment of additional consideration by the holder thereof, into such number of fully paid and non-assessable shares of the Company’s Common Stock as is determined by dividing the original issue price by the Conversion Price in effect at the time of conversion, subject to adjustment.

	•	After 24 months from the Closing of the Business Combination, in the event the closing share price of the Company’s Common Stock shall exceed 140% of the Conversion Price (as defined in the Merger Agreement) then in effect, then (i) each outstanding share of Preferred Stock shall automatically be converted into such number of shares of the Company’s Common Stock as is determined by dividing the original issue price by the Conversion Price in effect at the time of conversion and (ii) such shares may not be reissued by the Company, subject to adjustment. At the time of such conversion, the Company shall declare and pay all of the dividends that are accrued and unpaid as of the time of the conversion by either, at the option of the Company, (i) issuing additional Preferred Stock or (ii) paying cash.

	•	Immediately prior to any such optional conversion the Company shall pay all dividends on the Preferred Stock being converted that are accrued and unpaid as of such time by, either, at the option of the Company: (i) issuing additional Preferred Stock or (ii) paying cash.

During the three months ended March 31, 2024 the Company issued 621,500 Series A Preferred stock in conjunction with asset acquisitions of FeatherPay, Verifi Dental Limited and Teamworx LLC.

Common Stock Options

Certain employees and executives have been granted options or warrants that are compensatory in nature. A summary of option activity for the three months ended March 31, 2024 are presented below:

Options Outstanding	Number of Options		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term in Years		Aggregate Intrinsic Value

Balance Outstanding - January 1, 2024		776,328	$	3.75		8.0	$	-
Granted		3,000		1.27		9.8		-
Exercised		-		-		-		-
Forfeited		-		-		-		-
Balance Outstanding – March 31, 2024		779,328	$	3.73		7.7	$	-

Exercisable – March 31, 2024		575,235	$	3.72		7.7	$	-

Table of Contents

Nonvested Options	Number of Options			Weighted Average Grant Date Fair Value		Weighted Average Remaining Years to Vest

Nonvested - January 1, 2024		395,072		$	3.768		8.0
Granted		3,000			1.27		9.8
Vested		(193,979	)		3.72		7.7
Forfeited		-			-		-
Nonvested – March 31, 2024		204,093		$	3.76		7.8

Restricted Common Stock Compensation

The Board approved on January 3, 2023 134,049 shares of common stock related to the Chief Executive Officer for bonus related to 2022 service with a fair value of $356,000.

On March 13, 2023 the Company’s Board of Directors approved the grant of 5,027 shares of common stock to certain board members for services related to 2018 service.

In April 2023, the Company’s Board of Directors approved compensation for its Board Members and Committee Members for the year ended December 31, 2023. On an annual basis equivalent, Board Members are compensated $60,000, with additional compensation of $5,000 for being a Committee Member, an additional $5,000 for being a Chair of a Committee and $20,000 for being the Board Chair. Compensation is to be paid quarterly in arrears at the closing stock price of the last trading day of the quarter. The Company has recorded an expense of $105,000 and nil for the three months ended March 31, 2024 and 2023, respectively.

Common Stock Warrants

The Company typically issues warrants to individual investors and institutions to purchase shares of the Company’s Common Stock in connection with public and private placement fundraising activities. Warrants may also be issued to individuals or companies in exchange for services provided for the Company. The warrants are typically exercisable six months after the issue date, expire in five years, and contain a cash exercise provision and registration rights.

In May 2023, the Company entered into amendments with certain warrant holders whose warrants contained down round provisions and modified these warrants to remove such provisions from inception. As such the number and exercise of these warrants are set back to their original values as originally intended by the parties.

During the three months ending March 31, 2023, the Company issued no Common Stock Warrants.

During the three months ending March 31, 2024, the Company issued 69,000 Common Stock Warrants.

Table of Contents

As part of the Merger, all outstanding warrants were converted on a cashless basis into shares of common stock. As of March 30, 2024, the number of shares issuable upon exercise of the Common Stock Warrants were nil shares.

Common Stock Warrants Outstanding	Number of Warrants		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term in Years		Aggregate Intrinsic Value
Outstanding – December 31, 2023		45,129	$	2.09		4.81	$	-
Granted		69,000		1.36		4.76		-
Exercised		-		-		-		-
Cancelled		-		-		-		-
Outstanding – March 31, 2024		114,129	$	1.65		4.68	$	-

Preferred Stock Warrants

$2.00 Preferred Stock Warrants Outstanding	Number of Warrants		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term in Years		Aggregate Intrinsic Value
Outstanding – December 31, 2023		425,800	$	2.00		9.7	$	-
Granted		-		-		-		-
Exercised		-		-		-		-
Expired		-		-		-		-
Outstanding – March 31, 2024		425,800	$	2.00		9.4	$	-

$11.50 Preferred Stock Warrants Outstanding	Number of Warrants		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term in Years		Aggregate Intrinsic Value
Outstanding – December 31, 2023		10,122,313	$	11.50		9.7	$	-
Granted		-		-		-		-
Exercised		-		-		-		-
Expired		-		-		-		-
Outstanding – March 31, 2024		10,122,313	$	11.50		9.4	$	-

Table of Contents

$15.00 Preferred Stock Warrants Outstanding	Number of Warrants		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term in Years		Aggregate Intrinsic Value
Outstanding – December 31, 2023		1,000,000	$	15.00		9.7	$	-
Granted		-		-		-		-
Exercised		-		-		-		-
Expired		-		-		-		-
Outstanding – March 31, 2024		1,000,000	$	15.00		9.4	$	-

Equity Line of Credit

On September 12, 2023, the Company entered into a purchase agreement (the “Purchase Agreement”) with Arena Business Solutions Global SPC II, Ltd. on behalf of and for the account of Segregated Portfolio #8 – SPC #8 (“Arena”), pursuant to which Arena has committed to purchase up to $40 million (the “Commitment Amount”) of our common stock, at our direction from time to time, subject to the satisfaction of the conditions in the Purchase Agreement.

As consideration for Arena’s irrevocable commitment to purchase Common Stock upon the terms of and subject to satisfaction of the conditions set forth in the Purchase Agreement, upon execution of the Purchase Agreement, the Company agreed to issue a total of 291,259 shares of Common Stock equaling $600,000 (the “Commitment Fee Shares”) based on a price per share equal to the simple average daily VWAP of the Common Stock during the ten trading days immediately preceding the date on which the SEC declares the Registration Statement effective.

This line was cancelled in February 2024 and the Company expensed deferred costs of $1,008,376 related to this transaction which were recorded as financing costs.

Table of Contents

9. COMMITMENTS AND CONTINGENCIES

(A) LEASE COMMITMENTS

On September 22, 2021, the Company signed a six year and one month lease agreement for approximately 7,650 square feet for its new headquarters commencing on January 1, 2022, located in Ocoee, Florida. The lease provides for a five-year renewal term at the option of the Company. In April 2023, the Company entered into a lease agreement with its existing landlord of its Florida location for a lease of an additional 2,295 square feet of space beginning at the earlier of June 1, 2023 or completion of build out for a five year term.

As of March 31, 2024, undiscounted future lease obligations for the office spaces are as follows:

Lease Commitments
Less than 1 year		1-3 years		3-5 years		Total
$	361,424	$	1,019,651	$	41,386	$	1,422,461

Lease costs for the three months ended March 31, 2024 were $86,178 and cash paid for amounts included in the measurement of lease liabilities for the three months ended March 31, 2024 were $85,146. As of March 31, 2024, the following represents the difference between the remaining undiscounted lease commitments under non-cancelable leases and the lease liabilities:

Undiscounted minimum lease commitments	$	1,422,461
Present value adjustment using incremental borrowing rate		(295,742	)
Lease liabilities	$	1,126,719

(B) LITIGATION

On February 21, 2023, the Company received a notice under section 21 of Indian Arbitration and Conciliation Act, 1996 related to a dispute pursuant to a contract between the Company and a service provider, pursuant to which the service provider has asserted the Company has violated the terms of the contract and has claimed damages of approximately $635,000. The Company is evaluating the claims asserted against it and intends to defend itself vigorously in these proceedings; however, there can be no assurances that it will be successful in its efforts. The outcome of this matter is not expected to have a material effect on these financial statements.

(C) COMPENSATION

On March 29, 2024, the Compensation Committee approved a management incentive plan pursuant to which it agreed to issue ten-year options with an immediate vest to purchase shares of Company common stock at an exercise price of $3.10 per share, subject to the approval of the Plan Amendment at the Annual Meeting, to the following officers, among other employees, (i) Robert McDermott, Chief Executive Officer and President – options to purchase 1,817,742 shares of Company common stock; (ii) Archit Shah, Chief Financial Officer – options to purchase 482,259 shares of Company common stock; (iii) David Fidanza, Chief Information Officer – options to purchase 352,420 shares of Company common stock; (iv) Muralidar Chakravarthi, Chief Technology Officer – options to purchase 352,420 shares of Company common stock; (v) Jeffery Stellinga, Vice President – options to purchase 352,420 shares of Company common stock.

On March 29, 2024, the Compensation Committee awarded a cash and option bonus related to 2023 performance. The options are subject to subject to the approval of the Plan Amendment at the Annual Meeting, to the following officers, among other employees, (i) Robert McDermott, Chief Executive Officer and President – options to purchase 570,754 shares of Company common stock; (ii) Archit Shah, Chief Financial Officer – options to purchase 158,220 shares of Company common stock; (iii) David Fidanza, Chief Operating Officer – options to purchase 152,055 shares of Company common stock; (iv) Muralidar Chakravarthi, Chief Technology Officer – options to purchase 154,110 shares of Company common stock; (v) Jeffery Stellinga, Vice President – options to purchase 34,247 shares of Company common stock and (vi) Carly Garrison, Director of Sales – options to purchase 114,384 shares of Company common stock. In addition the cash awards are subject to the Company successfully raising in excess over $5,000,000 in equity during 2024 to the following officers, amount other employees;(i) Robert McDermott, Chief Executive Officer and President – $125,250; (ii) Archit Shah, Chief Financial Officer – $39,000; (iii) David Fidanza, Chief Operating Officer – $36,750 (iv) Muralidar Chakravarthi, Chief Technology Officer – $37,500; and (v) Carly Garrison, Director of Sales - $21,750.

Table of Contents

10. CONCENTRATION OF CREDIT RISK

Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash and trade accounts receivables. The Company places its cash with high-credit-quality financial institutions. At times, such cash may be in excess of the Federal Deposit Insurance Corporation (“FDIC”) insurance coverage limit of $250,000 per depositor. As a result, there could be a concentration of credit risk related to amounts on deposit in excess of FDIC insurance coverage. The Company has not experienced any losses due to these excess deposits and believes the risk is not significant. With respect to trade receivables, management routinely assesses the financial strength of its customers and, as a consequence, believes that the receivable credit risk exposure is limited.

The Company has historically provided financial terms to customers in accordance with what management views as industry norms. Access to the Company’s software products usually requires immediate payment but can extend several months under certain circumstances. Management periodically and regularly reviews customer account activity in order to assess the adequacy of allowances for doubtful accounts, considering such factors as economic conditions and each customer’s payment history and creditworthiness. If the financial condition of our customers were to deteriorate, or if they were otherwise unable to make payments in accordance with management’s expectations, we might have to increase our allowance for doubtful accounts, modify their financial terms and/or pursue alternative collection methods.

The Company has no significant customers (greater than 10% of total revenue) in its three-month 2024 revenue. The Company has accounts receivable concentration with three customers in 2024 representing 31% of total accounts receivables outstanding as of March 31, 2024, and one customer that represented 31% of accounts receivable outstanding as of December 31, 2023.

11. SEGMENT INFORMATION

The Company views its operations and manages its business as one operating segment which is the business of providing subscription-based software as a service (SaaS) and Managed IT (MSP/MSaaS) services and related non-recurring professional IT and other services. The Company aggregates is operating segments based on similar economic and operating characteristics of its operations.

The Company’s SaaS and Managed IT offerings are sold under monthly recurring revenue contracts are included in the Subscription software and services segment. Professional services and other revenue segment consists of non-recurring revenue, including the periodic sale and installation of IT related hardware and custom IT projects. Professional services and other revenue is recognized when services are performed.

Revenue types were as follows:

	For the Three Months Ended March 31
	2024		%			2023		%			% Change
Revenue:
Subscription software and services	$	2,595,050		95	%	$	1,703,815		93	%		52	%

Professional services and other		128,313		5	%		136,556		7	%		(6)	%

Total revenue	$	2,723,363		100	%	$	1,840,371		100	%		48	%

Table of Contents

12. BUSINESS COMBINATIONS

The Company accounts for business combinations under the acquisition method of accounting, in accordance with Accounting Standards Codification (“ASC”) Topic 805, Business Combinations, which requires assets acquired and liabilities assumed to be recognized at their fair values on the acquisition date. Any excess of the fair value of purchase consideration over the fair value of the assets acquired less liabilities assumed is recorded as goodwill. The fair values of the assets acquired and liabilities assumed are determined based upon the valuation of the acquired business and involves management making significant estimates and assumptions.

Ally Commerce, Inc dba FeatherPay (“FeatherPay”)

On January 1, 2024, the Company entered into an Asset Purchase Agreement (the “Agreement”) with Ally Commerce, Inc. dba FeatherPay (the “Seller”). The Seller was engaged in the business of healthcare billing and payment processing. Pursuant to the Agreement, the Company purchased the assets of the Seller utilized in the Seller’s business. As consideration for the acquired assets: (i) the Company paid to FeatherPay $500,000 in cash, and (ii) the Company agreed to issue to FeatherPay’s stockholders an aggregate of $4,800,000 worth of shares (the “Stock Consideration”) of Company’s Series A Preferred Stock, par value $0.0001 at $10.00 per share totaling 480,000 shares.

Teamworx LLC (“Teamworx”)

On January 1, 2024, the Company entered into an Asset Purchase Agreement with Teamworx LLC (“Teamworx”). Teamworx was engaged in the business of healthcare billing and payment processing. Pursuant to the Agreement, the Company purchased the assets of the Seller utilized in the Seller’s business. As consideration for the acquired assets: (i) the Company paid to Seller $125,000 in cash, and (ii) the Company agreed to issue to Seller $575,000 worth of shares of Company Series A Preferred Stock at $10.00 per share totaling 57,500 shares.

Verifi Dental Limited (“Verifi”)

On January 1, 2024, the Company entered into an Asset Purchase Agreement with Verifi Dental, Limited (the “Seller”). The Seller was engaged in the business of healthcare billing and payment processing. As consideration for the acquired assets: (i) the Company paid to Seller $360,000 in cash, and (ii) the Company agreed to issue to Seller $840,000 worth of shares of Company Series A Preferred Stock at $10.00 per share totaling 84,000 shares.

Certain fair values of acquired assets and assumed liabilities may be estimated at the acquisition date pending confirmation or completion of the valuation process. Where provisional values are used in accounting for a business combination, they may be adjusted retrospectively in subsequent periods within the measurement period when it reflects new information obtained about facts and circumstances that were in existence at the acquisition date. The measurement period cannot exceed one year from the acquisition date.

Table of Contents

The following table summarizes the consideration paid and the fair value of the assets acquired and liabilities assumed as of the dates detailed in the table:

	FeatherPay		Verifi Dental		Teamworx
Consideration Paid:	January 1, 2024		January 1, 2024		January 1, 2024
Cash	$	500,000	$	370,000	$	-
Note payable		-		-		125,000
Common stock		-		-		-
Series A preferred stock		4,800,000		840,000		575,000
	$	5,300,000	$	1,210,000	$	700,000

Fair values of identifiable assets acquired and liabilities assumed:

Assets acquired:
Cash	$	-	$	871	$	12,752
Accounts receivable		959		54,259
Customer relationships		-
Acquired technology		5,299,041		1,154,870		678,548
Deferred revenue						8,700
Total assets acquired		5,300,000		1,210,000		700,000

Net assets acquired	$	5,300,000	$	1,210,000	$	700,000

13. SUBSEQUENT EVENTS

On April 2, 2024 the Company entered into a promissory note in the principal amount of $200,000 with an existing investor. The maturity of the promissory note is June 30, 2024 and carries an interest rate of 16% per annum with interest and principal due at maturity. The note is subordinate to the Company’s senior lenders.

On April 29, 2024 the Company entered into a promissory note in the principal amount of $250,000 with an existing related party investor. The maturity of the promissory note is May 31, 2024 and carries an interest rate of 12% per annum. The note is subordinate to the Company’s senior lenders.

On May 8, 2024, The Company executed a securities purchase agreement (the “Purchase Agreement”) with an institutional investor (the “Investor”). Pursuant to the terms and conditions of the Purchase Agreement, the Investor agreed to purchase from the Company unsecured convertible notes in the aggregate principal amount of $304,700. At closing an aggregate principal amount of $304,700 will be issued upon the satisfaction of certain customary closing conditions in exchange for aggregate gross proceeds of $277,000, representing an original issue discount of 10%. On such date, the Company will also issue the Investors 17,034 shares of Company common stock (the “Commitment Shares”). The Note will mature 12 months from its respective issuance date (the “Maturity Date”), unless earlier converted. Commencing on the six-month anniversary of the issue date, the Company will be required to make monthly amortization payments pursuant to the Note of approximately 1/6th of the principal amount of the Note per month (the “Amortization Payments”). The Note will be the Company’s unsecured obligations and equal in right of payment with all of our other indebtedness and other indebtedness of any of our subsidiaries. The Notes were issued with an original issue discount of 10.0% per annum, and will not accrue additional interest during the term; provided that the interest rate of the Notes will automatically increase to 16% per annum (the “Default Rate”) upon the occurrence and continuance of an event of default. Each holder of Note may convert all, or any part, of the outstanding Note, at any time at such holder’s option, into shares of the Company’s common stock at an initial “Conversion Price” of $1,416 per share, which is subject to proportional adjustment upon the occurrence of any stock split, stock dividend, stock combination and/or similar transactions. With limited exceptions, if the Company at any time while a Note is outstanding, issues any common stock or securities entitling any person or entity to acquire shares of common stock (upon conversion, exercise or otherwise), at an effective price per share less than the Conversion Price then the Conversion Price shall be reduced to the same price as the new investment. A holder shall not have the right to convert any portion of a Note to the extent that, after giving effect to such conversion, the holder (together with certain related parties) would beneficially own in excess of 4.99%, or the “Maximum Percentage”, of shares of the Company’s common stock outstanding immediately after giving effect to such conversion. If the Company fails to make any Amortization Payments when due, then each holder may alternatively elect to convert all or any portion of such holder’s Notes at a conversion price equal to the lesser of (i) the Conversion Price, and (ii) 90% of the lowest VWAP of the common stock during the five (5) consecutive trading days immediately prior to such conversion. The Company received a waiver for untimely filing of its regulatory reporting requirements from the lender.

On May 13, 2024 with an effective date of May 1, 2024, the Company entered into a Note Amendment with a related party for the extension of a Promissory Note in the original amount of $260,000 with an original maturity date of April 30, 2024 to be extended to July 31, 2024. In consideration for the extension the Company will issue the holder 36,648 restricted shares of common stock at maturity. The inducement shares are subject to the Company’s ability to issue such shares in compliance with Nasdaq Listing Rule 5635(d) which will require the approval by the Company’s shareholders of certain proposals to be considered at the Company’s 2024 Annual Meeting to be held on May 31, 2024. To the extent the Company is unable to issue the Inducement Shares in compliance with Nasdaq Listing Rule 5635(d), the Company’s obligation to issue the Inducement Shares shall be tolled until such time as the Company is able to issue such Inducement Shares. The promissory note is subordinated to the Company’s senior lender.

On May 13, 2024 with an effective date of May 1, 2024, the Company entered into a Note Amendment with a related party for the extension of a Convertible Promissory Note in the original amount of $200,000 with an original maturity date of April 30, 2024 to be extended to July 31, 2024. In consideration for the extension the Company will issue the holder 28,625 restricted shares of common stock at maturity. The inducement shares are subject to the Company’s ability to issue such shares in compliance with Nasdaq Listing Rule 5635(d) which will require the approval by the Company’s shareholders of certain proposals to be considered at the Company’s 2024 Annual Meeting to be held on May 31, 2024. To the extent the Company is unable to issue the Inducement Shares in compliance with Nasdaq Listing Rule 5635(d), the Company’s obligation to issue the Inducement Shares shall be tolled until such time as the Company is able to issue such Inducement Shares. The convertible promissory note is subordinated to the Company’s senior lender.

On May 13, 2024, the Company entered into a Note Amendment with an extension of a Convertible Promissory Note in the original amount of $350,000 with an original maturity date of May 13, 2024 to be extended to July 31, 2024. In consideration for the extension the Company will issue the holder 51,539 restricted shares of common stock at maturity. The inducement shares are subject to the Company’s ability to issue such shares in compliance with Nasdaq Listing Rule 5635(d) which will require the approval by the Company’s shareholders of certain proposals to be considered at the Company’s 2024 Annual Meeting to be held on May 31, 2024. To the extent the Company is unable to issue the Inducement Shares in compliance with Nasdaq Listing Rule 5635(d), the Company’s obligation to issue the Inducement Shares shall be tolled until such time as the Company is able to issue such Inducement Shares. The convertible promissory note is subordinated to the Company’s senior lender.

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Statements made in this Quarterly Report on Form 10-Q, including without limitation this Management’s Discussion and Analysis of Financial Condition and Results of Operations, other than statements of historical information, are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may be identified by such words as “may,” “will,” “expect,” “anticipate,” “believe,” “estimate” and “continue” or similar words. We believe it is important to communicate our future expectations to investors. However, these forward-looking statements involve many risks and uncertainties, including the risk factors disclosed under the heading “Risk Factors” and under the heading entitled “Going Concern” in the “Notes to Condensed Consolidated Financial Statements” in Part I of this Quarterly Report on Form 10-Q. Our actual results could differ materially from those indicated in such forward-looking statements as a result of certain factors. We are under no duty to update any of the forward-looking statements after the date of this Report on Form 10-Q to conform these statements to actual results, other than to comply with the federal securities laws.

About the Company

Company History

The Company is a cloud-based software and technology company focused on increasing workflow productivity and customer profitability through its enterprise platform of applications and services.

Software as a Service (SaaS) Offerings

The Company currently markets secure Health Insurance Portability and Accountability Act (HIPAA) compliant cloud-based software as a service (SaaS) offering under the names of iCoreRx, iCorePDMP, iCoreEPCS, iCoreVerify, iCoreVerify+, iCoreHuddle, iCoreHuddle+, iCoreCodeGenius, iCoreExchange, iCoreCloud, iCorePay, iCoreSecure, and iCoreIT. The Company’s software is sold under annual recurring revenue subscriptions.

iCoreRx – iCoreRx is a HIPAA compliant electronic prescription SaaS solution that integrates with popular practice management and electronic health record systems. It saves time by selecting exact medications at available doses with built-in support from a drug directory and provides full support for Electronic Prescriptions for Controlled Substances (iCoreEPCS). It protects both the patient and provider by viewing the patient’s complete medication history. It also speeds up the process by allowing the doctor to create a “favorites” list for commonly used medication sets.

iCorePDMP is an add-on for iCoreRx that seamlessly integrates with state databases to automate prescription drug monitoring. Providers in many states are required to check the patient’s Prescription Drug Monitoring Program (PDMP) history before prescribing controlled substances. This service provides one-click real-time access to the state databases without the need to manually enter data. This tool also generates patient risk scores and an interactive visualization of usage patterns to help the prescriber identify potential risk factors. The prescriber can then use this report to make decisions on objective insight into potential drug misuse or abuse which will ultimately lead to improved patient safety and better patient outcomes.

iCoreVerify and iCoreVerify+ - iCoreVerify is a HIPAA compliant SaaS solution that automatically retrieves a patients insurance eligibility breakdown to verify their benefits seven (7) days in advance of their appointment and on-demand using iCoreConnect’s real time technology. Automation runs daily to verify insurance every patient on the schedule a full week in advance of their appointment date. The system returns results typically in less than one second for most responses. This substantially reduces the phone calls and labor hours for the practice. This tool integrates with most popular practice management systems. iCoreVerify+ adds a unique add-on service that augments iCoreConnect’s automation with a concierge service that turns around requests traditionally in less than 24 hours. It includes all carriers including non-digital ones and is customized to the client’s specialty.

iCoreHuddle and iCoreHuddle+ – iCoreHuddle is a powerful HIPAA compliant SaaS solution to instantly reveal the revenue potential of each patient. This product is currently limited to dental practices. The service connects to most popular practice management and electronic health record systems to optimize revenue realization. It provides the practice with a dashboard containing various metrics, analytics, and key performance indicators (“KPIs”). iCoreHuddle provides a daily view of patient schedules, including their outstanding balances, unscheduled treatment plans, recall information, procedure information and the amount of remaining insurance benefits. The software also provides one-click access to each patient’s insurance eligibility, including a detailed benefits and deductibles report. This tool aims to increase the workflow efficiency of the dentist’s practice by reducing the number of required lookups and clicks for each patient. iCoreHuddle+ offers enhanced analytical tools for practices to optimize their revenue generation process and workflows.

Table of Contents

iCoreCodeGenius – iCoreCodeGenius is a medical coding reference SaaS solution that provides the coding standards for the 10th revision of the International Classification of Diseases and Related Health Problems (ICD-10), a medical classification list published by the World Health Organization (WHO). It contains codes for diseases, signs and symptoms, abnormal findings, complaints, social circumstances, and external causes of injury and diseases.

iCoreExchange – iCoreExchange provides a secure, HIPAA compliant SaaS email solution using the direct protocol that allows doctors to send and receive secure email with attachments to and from other healthcare professionals in the network. iCoreExchange also provides a secure email mechanism to communicate with users outside the exchange e.g., patients and referrals. Users have the ability to build a community, access other communities and increase referrals and collaboration. Users can email standard office documents, JPEG, PDF as well as patient files with discrete data, which can then be imported and accessed on most Electronic Health Record (EHR) and Practice Management (PM) systems in a HIPAA compliant manner.

iCoreCloud - iCoreCloud offers customers the ability to backup their on-premise servers and computers to the cloud. iCoreCloud is a fully HIPAA compliant and automated backup solution. The data backed up is encrypted both in transit and while at rest. In case of full data loss, the mirrored data in the cloud can be seamlessly restored back to the practice on a new computer or a server. The data is stored encrypted in HIPAA compliant data centers with multiple layers of redundancy. The data centers are physically secure with restricted personnel and biometric access. The locations are also guarded by security 24 hours a day, 365 days a year.

iCorePay – iCorePay offers a seamless patient payment processing solutions for customers. iCorePay integrates into the practice workflow for payment and revenue cycle tracking.

iCoreSecure –We used our expertise and development capabilities from our HIPAA compliant iCoreExchange and developed iCoreSecure, an encrypted email solution for anyone that needs encrypted email to protect personal and financial data. iCoreSecure is a secure SaaS solution that solves privacy concerns in the insurance, real estate, financial and many other industry sectors that have a need for secure encrypted email.

iCoreIT -The trend in IT Services companies for over a decade has been to move away from a “Break/Fix ‘‘ model to a “Managed Service Provider (MSP)” and “Managed Software as a Service (MSaaS)” model with recurring revenue.

Managed IT Services (MSP and MSaaS)

The MSP/MSaaS approach, by using preventative measures, keeps computers and networks up and running while data is accessible and safeguarded. Installation of critical patches and updates to virus protection are automated. Systems are monitored and backed up in real-time. They are fixed or upgraded before they cause a service disruption. A Unified Threat Management solution is deployed to protect against virus, malware, SPAM, phishing and ransomware attacks. Remote technical support is a click away. All support is delivered at a predictable monthly cost.

By leveraging managed services with our expertise in cloud computing, our customers can scale their business without extensive capital investment or disruption in services.

We derive most of our revenue from subscriptions to our cloud-based SaaS and MSaaS offerings. Subscription revenue related to SaaS and MSaaS offerings account for 95% and 93% of our total revenue for the three months ended March 31, 2024 and 2023, respectively. We sell multiple offerings at different base prices on a subscription basis to meet the needs of the customers we serve.

Professional services and other revenue account for 5% and 7% of our total revenue for the three months ended March 31, 2024 and 2023, respectively. Professional services and other revenue include hardware, software, labor, and other revenues related to customer onboarding for SaaS/MSaaS services or one-time, non-recurring services. We expect professional services and other margins to range from moderately positive to break-even.

Table of Contents

Financing

We are currently funding our business capital requirements through sales of our common stock and debt arrangements. While we intend to seek additional funding, if revenue increases to a point where we are able to sustain ourselves and increase our budget to match our growth needs, we may significantly reduce the amount of investment capital we seek. The amount of funds raised, and revenue generated, if any, will determine how aggressively we can grow and what additional projects we will be able to undertake. No assurance can be given that we will be able to raise additional capital when needed or at all, or that such capital, if available, will be on terms acceptable to us. If we are unable to, or do not raise additional capital in the near future or if our revenue does not begin to grow as we expect, we will have to curtail our spending and downsize our operations.

Critical Accounting Policies and Estimates

Our discussion and analysis of financial condition and results of operations are based upon the financial statements, which have been prepared in accordance with generally accepted accounting principles as recognized in the United States of America. The preparation of these financial statements requires that we make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expenses, and disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that management believes to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.

Table of Contents

We believe that the most critical accounting policies relate to revenue recognition, software development capitalization and amortization, income taxes, stock-based compensation, and long-lived assets and goodwill. See Note 2 to the condensed consolidated financial statements.

Executive Summary

Financial Results for the Three Months Ended March 31, 2024

Our total revenue for the three months ended March 31, 2024, increased by 48% to $2,723,363 in comparison with $1,840,371 reported during the same period in 2023. Revenue growth is attributable to an increase in organic sales along with sales in new offerings from the asset acquisitions which contributed to overall revenue growth for the three months ended March 31, 2024. The Company continues to see organic growth in its SaaS based products.

The Company views its operations and manages its business as one operating segment which is the business of providing subscription-based software as a service (SaaS), Managed IT (MSaaS) and related non-recurring professional IT and other services. The Company aggregates is operating segments based on similar economic and operating characteristics of its operations.

Gross profit percentage was 81% and 73% for the three months ended March 31, 2024 and 2023, respectively. Gross Profit increased by $861,344 compared to the same period a year ago. Gross profit margin expansion was driven by a greater growth rate of sales in subscription software and services that carry higher gross margins than Professional Services and other revenue. We expect the growth rate of our SaaS and MSaaS subscription offerings to grow faster than our Professional Services and other revenue over time. We believe the higher growth rate of recurring revenue SaaS and MSaaS offerings should continue to provide a mix shift that will benefit gross margin rate going forward.

Business Highlights and Trends

	·	Product Traction. We continue to benefit from trends toward cloud-based SaaS offerings for improved workflow, productivity, and efficiency gains. As we have expanded our product offerings, we are seeing greater traction for all our software products across the entire platform.

	·	Business Development. The Company has pursued and won contracts with larger enterprise health care businesses and continues to do so. We currently have agreements with large State Associations, Dental Support Organizations (DSOs), Hospitals, and large insurance companies

	·	Capital raise. In the first three months of 2024, the company did not raise any funds from the sale of Common Stock and $1,423,093 in gross proceeds in the form of secured notes and convertible notes to fund operations and growth.

Results of Operations - Three Month Period Ended March 31, 2024 Compared to Three Month Period Ended March 31, 2023

Overview. The following table sets forth our selected financial data for the periods indicated below and the percentage dollar increase (decrease) of such items from period to period:

Three Month Period Ended March 31, 2024 Compared to the Three Month Period Ended March 31, 2023

	Three Months Ended
	March 31,			March 31,			%
	2024			2023			Incr/(Decr)
Revenue	$	2,723,363		$	1,840,371			48	%
Cost of sales		513,097			491,449			4	%
Gross profit		2,210,266			1,348,922

Expenses
Selling, general and administrative		4,519,898			2,411,071			87	%
Depreciation and amortization		732,553			288,909			154	%
Total operating expenses		5,252,451			2,699,980
Loss from operations		(3,042,185	)		(1,351,058	)

Other income (expense)
Interest expense		(226,467	)		(257,913	)		(12	)%
Finance charges		(1,302,697	)		(80,063	)		1,527	%
Change in fair value of forward purchase agreement		300,000			-			100	%
Income taxes		(54,000	)		-			100	%
Other expense		(397,621	)		-			100	%
Total other expense, net		(1,680,785	)		(337,976	)		397	%

Net loss	$	(4,722,970	)	$	(1,689,034	)		180	%

Preferred dividend		(448,000	)		-			100	%

Net loss attributable to common stockholders	$	(5170,970	)	$	(1,689,034	)		206	%

Revenues. Net revenues increased to $2,723,363 from $1,840,371 for the three months ended March 31, 2024 and 2023, respectively. The increase in revenue was driven by sales in the Company’s core SaaS offerings coupled with the addition of sales related to its asset acquisitions which are predominantly recurring services.

Cost of sales. Cost of sales for the three months ended March 31, 2024 and 2023 remained essentially flat as the Company was able to keep costs static. The Company has been able to continue leverage its capacity in its data centers and other systems to bring on customers while being able to keep costs related to support and service in check.

Selling, general and administrative expenses. Selling, general and administrative expenses for the three months ended March 31, 2024 and 2023 were $4,519,898 and $2,411,071, respectively. The increase between periods was primarily due to an increase in payroll expenses related to the cost to service its asset acquisitions and other general and administrative expenses to support the rate of growth.

Depreciation and amortization expenses. Depreciation and amortization expenses for the three months ended March 31, 2024 and 2023 were $732,553 and $288,909, respectively. The increase in depreciation and amortization reflects an increase primarily in amortization costs associated with the additional customer list of $1,559,144 and acquired technologies of $5,620,897 as part of the assets acquisitions in comparison to the comparative period.

Interest Expense. Interest expense for the three months ended March 31, 2024 and 2023 was $226,467 and $257,913, respectively. The decrease between periods was primarily due to the Company having lower average interest costs in 2024 than in 2023 and that the debt outstanding in 2024 was obtained near the reporting end which results in lower interest expense being reported.

Financing fee. Financing fee expenses for the three months ended March 31, 2024 and 2023 were $1,302,697 and $80,063 respectively. The increase between periods was primarily due to the Company expensing deferred financing fees of approximately $1,008,000 associated with its cancelled equity line of credit. In addition, the Company issued higher levels of convertible debt than in the comparative period resulting in additional financing costs being reported.

Change in fair value of forward purchase agreement. Change in fair value of forward purchase agreement for the three months ended March 31, 2024 and 2023 was $300,000 and $nil, respectively. The income relates to the derived fair value change of the shares underlying the forward purchase agreement market from the balance sheet date to estimated maturity date.

Other expense. Other expense for the three months ended March 31, 2024 and 2023 were $397,621 and $nil, respectively. Other expense reflects the final portion of a make whole agreement that the Company entered into in August of 2023, whereby the Company guaranteed the difference between the value of debt converted into shares at $10.00 per share and their ultimate sales price.

Income Tax. Income tax expense for the three months ended March 31, 2024 and 2023 were $54,000 and $nil, respectively and reflect the fact that the Company is now subject to taxes due to being registered in Delaware.

Preferred dividend. Preferred dividend for the three months ended March 31, 2024 and 2023 were $448,000 and $nil, respectively. The preferred dividend relates to dividends accrued for the Company’s issued and outstanding Series A Preferred Stock.

Table of Contents

LIQUIDITY, GOING CONCERN AND CAPITAL

For the three-month period ended March 31, 2024 the Company generated an operating loss of $3,042,185. In addition, the Company has an accumulated deficit and net working capital deficit of $120,509,730, and $10,906,673, respectively. The Company’s activities were primarily financed through private placements of equity securities and issuance of debt. The Company intends to raise additional capital through the issuance of debt and/or equity securities to fund its operations, although it has no commitments for such capital and there is no assurance that it will be successful in raising any additional capital. The Company is reliant on future fundraising to finance operations in the near future. If the Company fails to raise additional capital in the near future, it will be required to curtail or cease its operations. In light of these matters, there is substantial doubt that the Company will be able to continue as a going concern for a period of 12 months from the issuance date of these financial statements.

Management has introduced new lines of services with higher margins while it continues to develop strategic partnerships and has ramped up selling into the existing customer base as well as penetrate larger organizations with multiple customers while continuing to scope out additional areas of opportunity. While management believes in the viability of its strategy to increase revenues and in its ability to raise additional funds, there can be no assurances to that effect. Management’s ability to continue as a going concern is ultimately dependent upon its ability to continually increase the Company’s customer base and realize increased revenues from signed contracts. The financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

The primary factors that influence our liquidity include, but are not limited to, the amount and timing of our equity and debt raises, revenues, cash collections from our clients, capital expenditures, and investments in research and development.

The following table summarizes the impact of operating, investing and financing activities on our cash flows for the three-month periods ended March 31, 2024 and 2023 related to our operations:

	Three Month Ended
	March 31,			March 31,
	2024			2023
Net cash used in operating activities	$	(990,030	)	$	(1,152,215	)
Net cash used in investing activities		(1,204,437	)		(194,115	)
Net cash provided by financing activities		1,113,140			1,953,579
Net change in cash		(1,081,327	)		607,249
Cash and cash equivalents at beginning of the period		1,219,358			196,153
Cash and cash equivalents at end of the period	$	138,031		$	803,402

Operating Activities: Net cash used by operating activities of $990,030 for three-month period ended March 31, 2024 was $162,186 less than the $1,152,215 cash used by operations for the three-month period ended March 31, 2023. The decrease in cash utilized by operating activities was primarily attributable to a larger non-cash charge add backs over the comparative periods along with increases in accounts payable and accrued liabilities and lower prepaid expenses. Future spending on operating activities is expected to be funded by the sale of and issuance of additional shares of common stock.

Investing Activities: Net cash used by investing activities was $1,204,437 and $194,115 for the three-month period ended March 31, 2024 and 2023, respectively. The overall increase was mainly attributable to the cost of purchase related to the asset acquisitions of FeatherPay and Verifi Dental Limited. Future spending on investing activities is expected to be funded by the sale of and issuance of additional shares of common stock.

Financing Activities: Net cash provided by financing activities of $1,113,140 and $1,953,579 for the three-month period ended March 31, 2024 and 2023, respectively. The cash increase was obtained through the net issuance of debt less payments for 2024 while in 2023 the increase was attributed to net issuance of debt less payments along with common stock sale.

Table of Contents

Credit Facilities

On September 12, 2023, the Company entered into a purchase agreement (the “Purchase Agreement”) with Arena Business Solutions Global SPC II, Ltd. on behalf of and for the account of Segregated Portfolio #8 – SPC #8 (“Arena”), pursuant to which Arena committed to purchase up to $40 million (the “Commitment Amount”) of our common stock, at our direction from time to time, subject to the satisfaction of the conditions in the Purchase Agreement.

As consideration for Arena’s irrevocable commitment to purchase Common Stock upon the terms of and subject to satisfaction of the conditions set forth in the Purchase Agreement, upon execution of the Purchase Agreement, we agreed to issue a total of 291,259 shares of Common Stock equaling $600,000 (the “Commitment Fee Shares”) based on a price per share equal to the simple average daily VWAP of the Common Stock during the ten trading days immediately preceding the date on which the SEC declares the Registration Statement effective.

This line was cancelled in February 2024 and the Company expensed deferred costs of $1,008,376 related to this transaction which are reported as financing costs.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS

Not applicable.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Table of Contents

Disclosure controls and procedures are designed to ensure that information required to be disclosed by us in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure..

Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures as of the end of the fiscal quarter ended March 31, 2024, as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act.

Based on this evaluation, our Chief Executive Officer who is our principal executive officer and our Chief Financial Officer, who is our principal financial and accounting officer, have concluded that as of the end of the period covered by this report, our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) were not effective due to a material weakness in our internal control over financial reporting related to the Company’s accounting for complex financial instruments and material weakness related to our inability to adequately segregate responsibilities over the financial reporting process to ensure the accuracy of information. In addition, management has further identified deficiencies within its corporate governance practices, as the Company did not have the necessary controls in place to understand the impact on equity holders and monitor the issuance of instruments with down round features. To address this material weakness, management has devoted, and plans to continue to devote, significant effort and resources to the remediation and improvement of its internal control over financial reporting. While we have processes to identify and appropriately apply applicable accounting requirements, we plan to enhance these processes to better evaluate its research and understanding of the nuances of the complex accounting standards that apply to its financial statements. We plan to include providing enhanced access to accounting literature, research materials and documents and increased communication among its personnel and third-party professionals with whom it consults regarding complex accounting applications and we also plan to hire additional personnel to help provide adequate segregation of duties in the financial reporting process.

Changes to Internal Control Over Financial Reporting

We have not identified any change in our internal control over financial reporting during our most recently completed fiscal quarter that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

The Company from time to time, may be a party to various litigation, claims and disputes, arising in the ordinary course of business. While the ultimate impact of such actions cannot be predicted with certainty, we believe the outcome of these matters, except for that noted below, will not have a material adverse effect on our financial condition or results of operations.

On February 21, 2023, the Company received a notice under section 21 of Indian Arbitration and Conciliation Act, 1996 related to a dispute pursuant to contract between the Company and a service provider, pursuant to which the service provider has asserted the Company has violated the terms of the contract and has claimed damages of approximately $635,000. The Company is evaluating the claims asserted against it and intends to defend itself vigorously in these proceedings; however, there can be no assurances that it will be successful in its efforts.

ITEM 1A. RISK FACTORS

Except as set forth below, there have been no material changes from the risk factors disclosed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023.

The Company completed several acquisitions during the first quarter of 2024, which remain subject to integration risks.

In January 2024, the Company completed acquisitions of Ally Commerce, Inc. dba FeatherPay, Teamworx LLC, and Verifi Dental, Limited. Successful integration of the operations and personnel into our existing business places an additional burden on management and other internal resources. The diversion of management’s attention and any difficulties encountered in the transition and integration process could harm our business, financial condition, results of operations and prospects. Furthermore, the overall integration of the businesses may result in material unanticipated problems, expenses, liabilities, competitive responses, and loss of customers and other relationships. The difficulties of combining the operations of the companies include, among others, difficulties in conforming procedures, other policies, business cultures and compensation structures, assimilating employees, keeping existing customers and obtaining new customers. Our failure to meet the challenges involved in continuing to integrate the operations of these new assets or to otherwise realize any of the anticipated benefits of the acquisition could adversely impair our business and operations.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Information with respect to sales of unregistered shares of the Common Stock of the Company during the three months ended, which were not previously disclosed on Form 8-K are as follows: 85,174 shares of Common Stock and 621,500 shares of Preferred Stock. All such sales were to accredited investors and were made in reliance on Section 4(a)(2) of the Securities Act of 1933, as amended. The proceeds were used by the Company for working capital purposes.

Table of Contents

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

Not applicable.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

During the period covered by this Quarterly Report, none of the Company’s directors or executive officers has adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (each as defined in Item 408 of Regulation S-K under the Securities Exchange Act of 1934, as amended).

Table of Contents

ITEM 6. EXHIBITS

Exhibit No.		Description
2.1		Asset Purchase Agreement dated January 1, 2024 between iCoreConnect Inc. and Ally Commerce, Inc. (incorporated by reference to exhibit 2.1 of the Form 8-K filed January 4, 2024)
4.1		Form of Convertible Promissory Note issued December 29, 2023 (incorporated by reference to exhibit 4.1 of the Form 8-K filed January 5, 2024)
4.2		Form of Convertible Promissory Note issued February 1, 2024 (incorporated by reference to exhibit 4.1 of the Form 8-K filed February 7, 2024)
4.3		Form of Convertible Promissory Note issued February 9, 2024 (incorporated by reference to exhibit 4.1 of the Form 8-K filed February 15, 2024)
4.4		Form of Convertible Promissory Note issued February 2024 (incorporated by reference to exhibit 4.1 of the Form 8-K filed February 28, 2024)
4.5		Form of Indemnification and Advancement Agreement
10.1		Form of Securities Purchase Agreement related to the issuance of the Convertible Promissory Note issued December 29, 2023 (incorporated by reference to exhibit 10.1 of the Form 8-K filed January 5, 2024)
10.2		Subordinated Loan Agreement related to the issuance of the Convertible Promissory Note issued December 29, 2023 (incorporated by reference to exhibit 10.2 of the Form 8-K filed January 5, 2024)
10.3		Subordinated Note issued December 29, 2023 (incorporated by reference to exhibit 10.3 of the Form 8-K filed January 5, 2024)
10.4		Subordinated Security Agreement related to the issuance of the Convertible Promissory Note issued December 29, 2023 (incorporated by reference to exhibit 10.4 of the Form 8-K filed January 5, 2024)
10.5		Form of Warrant Amendment issued December 29, 2023 (incorporated by reference to exhibit 10.5 of the Form 8-K filed January 5, 2024)
10.5		Form of Note Amendment issued December 29, 2023 (incorporated by reference to exhibit 10.6 of the Form 8-K filed January 5, 2024)
10.6		Form of Securities Purchase Agreement related to the issuance of the Convertible Promissory Note issued February 1, 2024 (incorporated by reference to exhibit 10.1 of the Form 8-K filed February 7, 2024)
10.7		Forbearance Agreement (incorporated by reference to exhibit 4.2 of the Form 8-K filed February 15, 2024)
10.8		Form of Securities Purchase Agreement dated February 26, 2024 (incorporated by reference to exhibit 10.1 of the Form 8-K filed February 28, 2024)
10.9		Form of Registration Rights Agreement dated February 26, 2024 (incorporated by reference to exhibit 10.2 of the Form 8-K filed February 28, 2024)
10.10		Form of Note Amendment
31.1 *		Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2 *		Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1 *+		Certification of Principal Executive Officer Pursuant to Section 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2 *+		Certification of Principal Financial Officer Pursuant to Section 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS		Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).
101.SCH		Inline XBRL Taxonomy Extension Schema Document.
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB		Inline XBRL Taxonomy Extension Labels Linkbase Document.
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104		Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).

_____________

* Filed herewith.

+ The certifications on Exhibit 32 hereto are deemed not “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that Section. Such certifications will not be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.

Table of Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

iCoreConnect, Inc. (Registrant)

Date: May 15, 2024	By:	/s/ Robert McDermott
		Robert McDermott
		Chief Executive Officer
		(Principal Executive Officer)

Date: May 15, 2024	By:	/s/ Archit Shah
		Archit Shah
		Chief Financial Officer
		(Principal Accounting Officer)

nullnullnullnullnullnull

Cover - shares	3 Months Ended
Cover - shares	Mar. 31, 2024	May 15, 2024
Cover [Abstract]
Entity Registrant Name	iCoreConnect Inc.
Entity Central Index Key	0001906133
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	true
Entity Current Reporting Status	Yes
Document Period End Date	Mar. 31, 2024
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2024
Entity Ex Transition Period	true
Entity Common Stock Shares Outstanding		10,240,398
Entity File Number	001-41309
Entity Incorporation State Country Code	DE
Entity Tax Identification Number	86-2462502
Entity Address Address Line 1	529 E. Crown Point Road
Entity Address Address Line 2	Suite 250
Entity Address City Or Town	Ocoee
Entity Address State Or Province	FL
Entity Address Postal Zip Code	34761
City Area Code	888
Local Phone Number	810-7706
Security 12b Title	Common stock, par value $0.0001 per share
Trading Symbol	ICCT
Security Exchange Name	NASDAQ
Document Quarterly Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2024	Dec. 31, 2023
CONDENSED CONSOLIDATED BALANCE SHEETS
Cash	$ 138,031	$ 1,219,358
Accounts receivable, net	512,148	563,905
Prepaid expenses and other current assets	719,347	1,725,062
Total current assets	1,369,526	3,508,325
Property and equipment, net	188,895	202,421
Right of use lease asset - operating	1,060,267	1,122,412
Software development costs, net	1,125,368	903,412
Acquired technology, net	6,792,028	0
Customer relationships, net	2,729,920	2,980,412
Forward purchase agreement	5,784,556	5,484,556
Goodwill	1,484,966	1,484,966
Total long-term assets	19,166,000	12,178,179
TOTAL ASSETS	20,535,526	15,686,504
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts payable and accrued expenses	4,894,053	3,243,338
Operating lease liability, current portion	240,705	241,945
Notes payable, current portion	6,388,603	4,720,454
Related party notes payable	572,127	550,975
Deferred revenue	180,712	119,598
Total current liabilities	12,276,200	8,876,310
Long-term debt, net of current maturities	1,195,432	1,420,137
Operating lease liability, net of current portion	886,014	945,889
Total long-term liabilities	2,081,446	2,366,026
TOTAL LIABILITIES	14,357,646	11,242,336
STOCKHOLDERS' EQUITY
Preferred Stock par value $0.0001; 40,000,000 shares authorized; Issued and Outstanding: 4,376,709 as of March 31, 2024 and 3,755,209 as of December 31, 2023	438	376
Common Stock par value $0.0001; 100,000,000 shares authorized; Issued and Outstanding: 10,240,398 as of March 31, 2024 and 10,068,477 as of December 31, 2023	1,024	1,007
Additional paid-in-capital	126,386,147	119,481,543
Accumulated deficit	(120,209,729)	(115,038,758)
TOTAL STOCKHOLDERS' EQUITY	6,177,880	4,444,168
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 20,535,526	$ 15,686,504

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2024	Dec. 31, 2023
CONDENSED CONSOLIDATED BALANCE SHEETS
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	40,000,000	40,000,000
Preferred stock, shares issued	4,376,709	3,755,209
Preferred stock, shares outstanding	4,376,709	3,755,209
Common Stock, par value	$ 0.0001	$ 0.0001
Common Stock, shares authorized	100,000,000	100,000,000
Common Stock, shares issued	10,240,398	10,068,477
Common Stock, shares outstanding	10,240,398	10,068,477

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
Revenue, net	$ 2,723,363	$ 1,840,371
Cost of sales	513,097	491,449
Gross profit	2,210,266	1,348,922
Expenses
Selling, general and administrative	4,519,898	2,411,071
Depreciation and amortization	732,553	288,909
Total operating expenses	5,252,451	2,699,980
Loss from operations	(3,042,185)	(1,351,058)
Other income (expenses)
Interest expense	(226,467)	(257,913)
Finance charges	(1,302,697)	(80,063)
Change in fair value of forward purchase agreement	300,000	0
Income taxes	(54,000)	0
Other expense	(397,621)	0
Total other expenses	(1,680,785)	(337,976)
Net loss	(4,722,970)	(1,689,034)
Preferred dividend	(448,000)	0
Net loss attributable to common stockholders	$ (5,170,970)	$ (1,689,034)
Net loss per share available to common stockholders, basic and diluted	$ (0.51)	$ (0.26)
Weighted average number of shares, basic and diluted	10,100,426	6,490,738

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY (DEFICIT) (UNAUDITED) - USD ($)	Total	Common Stock	Preferred Stock	Additional Paid-In Capital	Retained Earnings (Accumulated Deficit)
Balance, shares at Dec. 31, 2022		6,076,078
Balance, amount at Dec. 31, 2022	$ (12,744,813)	$ 608	$ 0	$ 86,372,975	$ (99,118,396)
Balances at January 1, 2023 (as previously reported) shares		181,320,528
Balances at January 1, 2023 (as previously reported) amount	(2,501,504)	$ 181,321	0	86,192,262	(88,875,087)
Retroactive application of reverse capitalization, shares		(175,244,450)
Retroactive application of reverse capitalization, amount	(10,243,309)	$ (180,713)	0	180,713	(10,243,309)
Stock issued for cash, shares		180,966
Stock issued for cash, amount	540,000	$ 18		539,982
Origination fee in convertible debt agreement, amount	80,063			80,063
Stock issued for conversion of debt, shares		236,502
Stock issued for conversion of debt, amount	685,333	$ 24		685,309
Stock compensation expense, shares		5,027
Stock compensation expense, amount	272,983	$ 1		272,982
Net Income (Loss)	(1,689,034)				(1,689,034)
Balance, shares at Mar. 31, 2023		6,498,573
Balance, amount at Mar. 31, 2023	(12,855,468)	$ 651	$ 0	87,951,311	(100,807,430)
Balance, shares at Dec. 31, 2023		10,068,477	3,755,209
Balance, amount at Dec. 31, 2023	4,444,168	$ 1,007	$ 376	119,481,543	(115,038,758)
Origination fee in convertible debt agreement, amount	$ 182,004	$ 8		181,996
Stock compensation expense, shares	86,747	86,747
Stock compensation expense, amount	$ 507,679	$ 9		507,670
Net Income (Loss)	(5,170,970)	$ 0		0	(5,170,970)
Origination fee in convertible debt agreement, shares		85,174
Stock issued for purchase of Verifi Dental Limited, shares			84,000
Stock issued for purchase of Verifi Dental Limited, amount	840,000		$ 8	839,992
Stock issued for purchase of FeatherPay, shares			480,000
Stock issued for purchase of FeatherPay, amount	4,800,000		$ 48	4,799,952
Stock issued for the purchase of Teamworx, shares			57,500
Stock issued for the purchase of Teamworx, amount	575,000		$ 6	574,994
Balance, shares at Mar. 31, 2024		10,240,398	4,376,709
Balance, amount at Mar. 31, 2024	$ 6,177,880	$ 1,024	$ 438	$ 126,386,147	$ (120,209,729)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (5,170,970)	$ (1,689,034)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	13,526	5,733
Amortization expense	719,028	283,176
Finance fee	182,922	80,063
Change in allowance for doubtful accounts	123,797	35,982
Stock compensation expense	507,670	272,983
Non-cash interest expense	226,466	15,535
Change in fair value of forward purchase agreement	(300,000)	0
Changes in operating assets and liabilities:
Accounts receivable	(16,822)	36,449
Prepaid expenses and other current assets	1,005,715	(56,279)
Right of use asset, net of lease liability	1,030	1,981
Accounts payable and accrued expenses	1,650,714	(192,149)
Deferred revenue	66,894	53,345
NET CASH USED IN OPERATING ACTIVITIES	(990,030)	(1,152,215)
INVESTING ACTIVITIES
Cash portion of consideration paid to acquire assets - Verifi Dental Limited	(370,000)	0
Cash portion of consideration paid to acquire assets - FeatherPay	(500,000)	0
Purchase of capital assets	0	(40,769)
Additions to capitalized software	(334,437)	(153,346)
NET CASH USED IN INVESTING ACTIVITIES	(1,204,437)	(194,115)
FINANCING ACTIVITES
Net proceeds from debt	1,423,093	2,000,000
Payments on debt	(309,953)	(586,421)
Proceeds from issuance of common stock	0	540,000
NET CASH PROVIDED BY FINANCING ACTIVITIES	1,113,140	1,953,579
NET CHANGE IN CASH	(1,081,327)	607,249
CASH AT BEGINNING OF THE PERIOD	1,219,358	196,153
CASH AT END OF THE PERIOD	138,031	803,402
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid during the period for interest	$ 74,921	$ 215,821

NATURE OF OPERATIONS

3 Months Ended

Mar. 31, 2024

NATURE OF OPERATIONS

NATURE OF OPERATIONS

1. NATURE OF OPERATIONS

Business Combinations

Going Concern and Liquidity

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

3 Months Ended

Mar. 31, 2024

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

2. SUMMARY OF SIGNFICANT ACCOUNTING POLICES

Basis of Presentation

Accounts Receivable and Allowance for Doubtful Accounts

Software Development Costs and Acquired Software

Long-Lived Assets and Goodwill

Revenue Recognition

We have 6 primary sources of revenue as of March 31, 2024 and December 31, 2023:

We have 6 primary sources of revenue

	1.	Electronic Prescription Software
	2.	Insurance Verifications
	3.	ICD-10 Medical Coding Software
	4.	Encrypted and HIPAA Compliant Secure email
	5.	Analytics
	6.	MSaaS software

1) Electronic Prescription software services are provided on an annual subscription basis using the software as a service (‘SaaS’) model with revenue recognized ratably over the contract term.

2). Insurance verification services are provided on an annual subscription basis using SaaS model with revenue recognized ratably over the contract term.

3) ICD-10 Medical Coding services are provided on an annual subscription basis using the software as a SaaS model with revenues recognized ratably over the contract term.

4) Encrypted and HIPAA compliant and secure email services are provided on an annual subscription basis using the SaaS model with revenues recognized ratably over the contract term.

6) MSaaS software services are provided on an annual subscription basis using the software as a service (‘SaaS’) model with revenue recognized ratably over the contract term.

Advertising Costs

Accounting for Derivative Instruments

Financial Instruments With Down Round Features

Income Taxes

Net Loss Per Share

Beneficial Conversion Features and Warrants

Leases

Business Combinations

Allowance for Credit Losses

Recently Issued Accounting Pronouncements

Adopted

Not Yet Adopted

BUSINESS COMBINATION AND RECAPITALIZATION

3 Months Ended

Mar. 31, 2024

BUSINESS COMBINATION AND RECAPITALIZATION

BUSINESS COMBINATION AND RECAPITALIZATION

3. BUSINESS COMBINATION AND RECAPITALIZATION

The following table details the number of shares of Company Common Stock issued immediately following the consummation of the Business Combination:

	Common Stock			Preferred Stock

Common stock of FGMC outstanding prior to business combination		8,050,000			-
Less: Redemptions of FGMC common stock		(6,460,059	)		-
Common stock held by former FGMC shareholders		1,589,941			-
FGMC sponsor shares		1,692,374			-
Underwriter shares		40,250			-
Sponsor shares transferred for services		2,000			-
Sponsor shares transferred for non-redemption		373,126			-
Shares issued related to extension note		84,500			-
Total FGMC common shares outstanding prior to conversion to preferred stock		3,782,191			-
Conversion of existing FGMC common stockholders to new preferred stock		(3,782,191	)		3,782,191
Shares issued to Old iCore stockholders for purchase consideration		8,095,706			-
Total		8,095,706			3,782,191

The following table reconciles the elements of the Business Combination to the Company’s condensed consolidated statement of changes in stockholders’ equity (deficit):

	Amount
Cash - FGMC trust (net of redemptions)	$	17,002,897
Cash transferred to Forward Purchase Agreement		(12,569,810	)
Gross proceeds		4,433,087
Less: FGMC and Old iCore transaction costs paid		(4,433,087	)
Effect of Business Combination, net of redemptions and transaction costs	$	-

All existing FGMC warrants were converted into Preferred Stock warrants with the same terms and conditions:

Holder	Number of Warrants		Strike Price
Underwriter		600,000	$	2.00
Sponsor and Investors		10,122,313	$	11.50
Sponsor		1,000,000	$	15.00

INTANGIBLE ASSETS AND GOODWILL

3 Months Ended

Mar. 31, 2024

INTANGIBLE ASSETS AND GOODWILL

GOODWILL AND OTHER INTANGIBLE ASSETS

4. INTANGIBLE ASSETS AND GOODWILL

The following table sets forth the gross carrying amounts and accumulated amortization of the Company’s intangible assets as of March 31, 2024 and December 31, 2023:

	Gross Carrying Amount		Impairment			Accumulated Amortization			Net Carrying Amount
Definite-lived intangible assets:
Capitalized software	$	3,741,511	$	-		$	(2,838,099	)	$	903,412
Customer relationships		5,272,578		(105,676	)		(2,186,490	)		2,980,412
Acquired technology		1,527,186		-			(1,527,186	)		-
Total definite-lived intangible assets at December 31, 2023		10,541,275		(105,676	)		(6,551,775	)		3,883,824

Capitalized software		4,075,948		-			(2,950,580	)		1,125,368
Customer relationships		5,166,903		-			(2,436,983	)		2,729,920
Acquired technology		7,148,083		-			(356,055	)		6,792,028
Total definite-lived intangible assets at March 31, 2024	$	16,390,934		-		$	(5,743,618	)	$	10,647,316

The following table sets forth the changes in the carrying amount of goodwill for the three months ended March 31, 2024 and year ended December 2023:

	Total
Balance at December 31, 2023	$	1,484,966
2024 acquisitions		-
Balance at March 31, 2024	$	1,484,966

FORWARD PURCHASE AGREEMENT

3 Months Ended

Mar. 31, 2024

FORWARD PURCHASE AGREEMENT

FORWARD PURCHASE AGREEMENT

5. FORWARD PURCHASE AGREEMENT

Upon the Business Combination closing, 100,000 Purchased Shares were deemed to be “Commitment Shares” and the remaining Purchased Shares were deemed to be “Prepaid Forward Purchase Shares”.

	·	the occurrence of a “Registration Failure” (as defined in the FPA), and

	·	the date that is twelve months after the closing of the Business Combination (the “Maturity Date”), then, for any Common Stock underlying the Prepaid Forward Purchase Shares not sold by the Purchaser, the Purchaser shall, on the 25th trading day after the Maturity Date (the “Payment Date”), pay the Company an amount equal to (i) the number of Prepaid Forward Purchase Shares that the Purchaser held on the Maturity Date, multiplied by (ii) the lowest daily volume weighted average price per share of FGMC Common Stock during the twenty trading days beginning on the day after the Maturity Date less $0.15.

NOTES PAYABLE

3 Months Ended

Mar. 31, 2024

NOTES PAYABLE

NOTES PAYABLE

6. NOTES PAYABLE

		March 31,			December 31,
		2024			2023
(2)	Note bearing interest at 18% due October 1, 2026		25,325			27,540
(3)	Secured Promissory Note bearing interest at 17.5% due February 28, 2026		1,753,761			1,988,793
(4)	Promissory Note bearing interest at 12%, due October 31, 2023		-			38,609
(5)	Convertible Note bearing interest at 12% due May 13, 2024		369,560			388,380
(6)	Convertible Note bearing interest at 12%, due October 31, 2024		564,513			569,391
(6)	Convertible Note bearing interest at 12%, due December 18, 2024		572,407			574,961
(7)	Convertible Note bearing interest at 12%, due December 19, 2024		79,813			80,722
(8)	Convertible Note bearing interest at 12%, due December 19, 2024		79,813			80,509
(5)	Convertible Note bearing interest at 12%, due December 28, 2024		125,092			114,781
(1)	Convertible Note bearing interest at 12%, due June 1, 2024		527,603			473,743
(9)	Promissory Note bearing interest at 15%, due December 26, 2024		2,074,795			2,000,000
(21)	Promissory Note bearing interest at 12%, due May 3, 2024		127,425			-
(11)	Convertible Note bearing interest at 12%, due February 1, 2025		57,629			-
(12)	Convertible Note bearing interest at 12%, due February 1, 2025		5,763			-
(13)	Convertible Note bearing interest at 16%, due February 26, 2025		404,225			-
(13)	Convertible Note bearing interest at 16%, due February 26, 2025		1,280,047			-
	Total notes payable		8,047,771			6,337,429
	Less: Unamortized debt discounts		(104,167	)		-
	Less: unamortized financing costs		(359,569	)		(196,837	)
	Total notes payable, net of financing costs		7,584,035			6,140,592
	Less current maturities		(6,388,603	)		(4,720,455	)
	Total Long-Term Debt	$	1,195,432		$	1,420,137

1.	On February 9, 2024, the Company issued a convertible note entered into a securities purchase agreement with an investor with an effective date of December 29, 2023, pursuant to which the Company in principal amount of $473,743 in exchange for the conversion of a payable in the amount of $473,743. The maturity of the convertible note is June 1, 2024 and carries an interest rate of 12% per annum and is convertible into Company common stock at a conversion rate equal to 100% of the closing price of the Company’s common stock on December 29, 2023, provided such conversion right is subject to approval of the transaction by the Company’s shareholders.

2.	In November 2021, the Company signed a $40,071 equipment finance agreement with a maturity date 60 months after issuance from a third-party financing company. Payments of principal and interest of $791 are due monthly.

3.	On February 28, 2022, the Company signed a $2,000,000 secured promissory note with a maturity date 48 months after issuance and received in exchange $1,970,000 net of fees. An Interest charge of 17.5% per annum shall accrue, with interest only payments being made for the first six months after which both interest and principal will be due. The Company has right of prepayment subject to certain minimum interest payments being made. The Prepayment Fee shall be (i) equal to 6 months’ interest that would have accrued with regard to the prepaid principal, if prepaid prior to the 2nd anniversary of the date of the Initial Advance or Subsequent Advance, as applicable, and (ii) equal to 3 months’ interest that would have accrued with regard to the prepaid principal, if prepaid on or after the 2nd anniversary and prior to the 3rd anniversary of the date of the Initial Advance or Subsequent Advance, as applicable. Additionally, the Company has the following covenant requirements; maintaining a minimum cash balance of $150,000 in its combined bank accounts as well as entering into a Deposit Account Control Agreement; monthly financial reporting requirements and certifications; obtaining other indebtedness without consent; merge, consolidate or transfer assets; pledge assets as collateral; or guarantee without consent of the Lender. On February 12, 2024, the Company entered into a Forbearance Agreement with an effective date of December 31, 2024 whereby the Company agreed to make $300,000 payment to cure certain defaults under the original Loan Agreement. In addition, the Company agreed to increase the default rate of interest in the Loan Agreement, report certain financial and cash metrics on a weekly basis, budgetary updates as well as pay down of balance of 10% of all financing raised over $500,000, in exchange for interest only payments until July 2024 and waiver of all covenants

4.		In September 2023 the Company entered into a sixty-day Promissory Note (“Note”) in the amount of $1,200,000 related to its purchase of the assets of Preferred Dental Development LLC. The Note carries an interest of 12% per annum and is subordinated to the Company’s senior lenders. The principal balance of the note was fully repaid in December 31, 2023 with only the interest portion of $38,609 outstanding as of December 31, 2023. The note was fully repaid in January 2024. The promissory note was subordinated to the Company’s senior lenders.

5.		In October 2023, the Company entered into a promissory note for $350,000. The maturity of the Promissory Note is May 13, 2024 and carries an interest rate of 12% per annum and is initially convertible into Company common stock at a conversion rate of $1.85 per share. In conjunction with the Promissory Note, the Company also issued a five-year warrant to purchase 24,500 shares of Company common stock with an exercise price of $2.04. The value of the warrants of 13,498 as determined by a Black-Scholes calculation is separated from the value of the note and expensed equally over the term of the note as a financing fee. On December 28, 2023, the Company entered into a securities purchase agreement with the existing investor, pursuant to which the Company issued the investor a convertible note in principal amount of $100,000. The maturity of the convertible note is December 28, 2024 and carries an interest rate of 12% per annum and is initially convertible into Company common stock at a conversion rate equal to 120% of the closing price of the Company’s common stock on the date of issuance which was $1.31 or $1.57 for the share price of conversion. In December 2023, the Company entered into an amendment with holder of an Amendment to Convertible Promissory Notes issued in October 2023 whereby the holder of the Note agreed that the Note would not be convertible into shares of Company Common Stock unless and until the Company’s shareholders approve such conversion per NASDAQ Listing Rule 5635(d). The Company and the Note holder also entered into amendments to the warrants to purchase common stock issued in connection with the issuance of the Note, pursuant to which the holder of the Warrants agreed that the Warrants would not become exercisable unless and until the Company’s shareholders approve the exercise of the Warrants pursuant to NASDAQ Listing Rule 5635(d). The promissory notes are subordinated to the Company’s senior lender.

6.		In October 2023, the Company entered into a securities purchase agreement with an investor, pursuant to which the Company issued the investor a Convertible Promissory Note in principal amount of $500,000. The maturity of the Convertible Promissory Note is October 31, 2024 and carries an interest rate of 12% per annum and is initially convertible into Company common stock at a conversion rate equal to 120% of the closing price of the Company’s common stock on the date of issuance which was $1.58 or $1.90. In December 2023, the Company entered into a securities purchase agreement with the existing investor, pursuant to which the Company issued the investor a convertible note in principal amount of $500,000. The maturity of the convertible note is December 18, 2024 and carries an interest rate of 12% per annum and is initially convertible into Company common stock at a conversion rate equal to 120% of the closing price of the Company’s common stock on the date of issuance which was $2.31 or $2.77 for the share price of conversion. The promissory notes are subordinated to the Company’s senior lender.

7.		In December 2023, the Company entered into a securities purchase agreement pursuant to which the Company issued a convertible note in principal amount of $70,000. The maturity of the convertible note is December 19, 2024 and carries an interest rate of 12% per annum and is initially convertible into Company common stock at a conversion rate equal to 120% of the closing price of the Company’s common stock on the date of issuance which was $1.69 or $2.03 for the share price of conversion. The promissory notes are subordinated to the Company’s senior lender.

8.		In December 2023, the Company entered into a securities purchase agreement pursuant to which the Company issued a convertible note in principal amount of $70,000. The maturity of the convertible note is December 19, 2024 and carries an interest rate of 12% per annum and is initially convertible into Company common stock at a conversion rate equal to 120% of the closing price of the Company’s common stock on the date of issuance which was $1.69 or $2.03 for the share price of conversion. The promissory notes are subordinated to the Company’s senior lender.

9.		In December 2023, the Company issued a subordinated note to a service provider in principal amount of $2,000,000 in exchange for conversion of an account payable in the amount of $2,000,000. The maturity of the subordinated note is December 26, 2024 and carries an interest rate of 15% per annum and is to be paid in interest only installments for three months followed with a ballon payment in month four and then a combination of principal and interest payments for the remaining term. The note is secured by the assets of the Company and is junior to the security interest of the Company’s senior lender. As part of the note payable the Company agreed to purchase investor relation consulting services totaling $200,000 payable in quarterly installments beginning in January 2024.

10.	On January 1, 2024 the Company entered into a promissory note with Teamworx for $125,000 due January 31, 2024 with no interest. On February 1, 2024, the note was extended to February 29, 2024 with 12% with principal and interest due at maturity. On March 1, 204 the note was extended again to April 30, 2024 with principal and interest due at maturity. This note was further extended to May 6, 2024 under the same terms.

11.		On February 1, 2024, the Company entered into a securities purchase agreement with an investor, pursuant to which the Company issued the investor a convertible note in principal amount of $50,000 in exchange for $50,000. The maturity of the convertible note is February 1, 2025 and carries an interest rate of 12% per annum and is initially convertible into Company common stock at a conversion rate equal to 120% of the closing price of the Company’s common stock on the date of issuance. The convertible note is being sold and issued without registration under the Securities Act of 1933, as amended (the “Securities Act”), in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D promulgated under the Securities Act as sales to an accredited investor, and in reliance on similar exemptions under applicable state laws.

12.		On February 1, 2024, the Company entered into a securities purchase agreement with an investor, pursuant to which the Company issued the investor a convertible note in principal amount of $5,000 in exchange for $5,000. The maturity of the convertible note is February 1, 2025 and carries an interest rate of 12% per annum and is initially convertible into Company common stock at a conversion rate equal to 120% of the closing price of the Company’s common stock on the date of issuance. The convertible note is being sold and issued without registration under the Securities Act of 1933, as amended (the “Securities Act”), in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D promulgated under the Securities Act as sales to an accredited investor, and in reliance on similar exemptions under applicable state laws.

13.		On February 26, 2024, The Company executed a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (the “Investors”). Pursuant to the terms and conditions of the Purchase Agreement, the Investors agreed to purchase from the Company unsecured convertible notes in the aggregate principal amount of up to $2,375,000. The Purchase Agreement contemplates funding of the investment across two tranches. At the first closing (the “Initial Closing”) an aggregate principal amount of $1,375,000 will be issued upon the satisfaction of certain customary closing conditions in exchange for aggregate gross proceeds of $1,250,000, representing an original issue discount of 10%. On such date (the “Initial Closing Date”), the Company will also issue the Investors 85,174 shares of Company common stock (the “Commitment Shares”). Subject to satisfying the conditions discussed below, the Company has the right under the Purchase Agreement, but not the obligation, to require that the Investors purchase additional Notes at one additional closing. Upon notice, the Company may require that the Investors purchase an additional aggregate principal amount of $1,100,000 of Notes, in exchange for aggregate gross proceeds of $1,000,000, if, among other items, (i) the Registration Statement (as described below) is effective; and (ii) the Shareholder Approval (as described below) has been obtained. The Notes will mature 12 months from their respective issuance date (the “Maturity Date”), unless earlier converted. Commencing on the six-month anniversary of the issue date, the Company will be required to make monthly amortization payments pursuant to the Note of approximately 1/6th of the principal amount of the Note per month (the “Amortization Payments”). The Notes will be the Company’s unsecured obligations and equal in right of payment with all of our other indebtedness and other indebtedness of any of our subsidiaries. The Notes were issued with an original issue discount of 10.0% per annum, and will not accrue additional interest during the term; provided that the interest rate of the Notes will automatically increase to 16% per annum (the “Default Rate”) upon the occurrence and continuance of an event of default. Each holder of Notes may convert all, or any part, of the outstanding Notes, at any time at such holder’s option, into shares of the Company’s common stock at an initial “Conversion Price” of $1.848 per share, which is subject to proportional adjustment upon the occurrence of any stock split, stock dividend, stock combination and/or similar transactions. With limited exceptions, if the Company at any time while a Note is outstanding, issues any common stock or securities entitling any person or entity to acquire shares of common stock (upon conversion, exercise or otherwise), at an effective price per share less than the Conversion Price then the Conversion Price shall be reduced to the same price as the new investment. A holder shall not have the right to convert any portion of a Note to the extent that, after giving effect to such conversion, the holder (together with certain related parties) would beneficially own in excess of 4.99%, or the “Maximum Percentage”, of shares of the Company’s common stock outstanding immediately after giving effect to such conversion. If the Company fails to make any Amortization Payments when due, then each holder may alternatively elect to convert all or any portion of such holder’s Notes at a conversion price equal to the lesser of (i) the Conversion Price, and (ii) 90% of the lowest VWAP of the common stock during the five (5) consecutive trading days immediately prior to such conversion. The Company received a waiver for untimely filing of its regulatory reporting requirements from the lender.

RELATED PARTY TRANSACTIONS

3 Months Ended

Mar. 31, 2024

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS

7. RELATED PARTY TRANSACTIONS

		March 31,			December 31,
		2023			2023
(2)	Related Party Promissory Note bearing interest at 18%, due December 31, 2023	$	-		$	249,855
(1)	Related Party Promissory Note bearing interest at 12%, due December 31, 2023		-			225,797
(1)	Related Party Convertible Promissory Note bearing interest at 12%, due May 26, 2024		113,708			96,753
(2)	Related Party Promissory Note bearing interest at 20%, due April 30, 2024		280,753			-
(1)	Related Party Convertible Promissory Note bearing interest at 12%, due April 30, 2024		223,975			-
	Total notes payable		618,436			572,405
	Less: Unamortized debt discounts		-			-
	Less: unamortized financing costs		(46,309	)		(21,431	)
	Total notes payable, net of financing costs		572,127			550,974
	Less current maturities		(572,127	)		(550,974	)
	Total Long-Term Debt	$	-		$	-

1.	In October 2023 the Company entered into two separate new notes with a related party; (a) $200,000 Promissory Note with 12% interest per annum which shall be paid on the maturity date which is December 31, 2023. In conjunction with the issuance of the Promissory Note, the Company also issued the investor a five-year warrant (the “Warrant”) to purchase 14,000 shares of Company common stock with an exercise price of $2.16 per share, which was 120% of the closing price of the Company’s common stock on the date of issuance; (b) the Company issued the investor a convertible promissory note in principal amount of $94,685.91 The maturity of the Convertible Promissory Note is May 26, 2024 and carries an interest rate of 12% per annum and is initially convertible into Company common stock at a conversion rate of $1.80 per share, which was the closing price of the Company’s common stock on the date of issuance. In conjunction with the Convertible Promissory Note, the Company also issued the investor 6,629 shares of Company common stock and a five-year warrant to purchase 6,629 shares of Company common stock with an exercise price of $2.15 per share, which was 120% of the closing price of the Company’s common stock on the date of issuance. In December 2023, the Company entered into an amendment with holder of an Amendment to Convertible Promissory Notes issued in October 2023 whereby the holder of the Note agreed that the Note would not be convertible into shares of Company Common Stock unless and until the Company’s shareholders approve such conversion per NASDAQ Listing Rule 5635(d). The Company and the Note holder also entered into amendments to the warrants to purchase common stock issued in connection with the issuance of the Note, pursuant to which the holder of the Warrants agreed that the Warrants would not become exercisable unless and until the Company’s shareholders approve the exercise of the Warrants pursuant to NASDAQ Listing Rule 5635(d). On April 8, 2024 with an effective date of January 1, 2024, the Company entered into a securities purchase agreement with a related party pursuant to which the Company issued the related party a convertible note in the principal amount of $200,000 in exchange for $200,000. The maturity of the convertible note is April 30, 2024 and carries an interest rate of 12% per annum and is initially convertible into Company common stock at a conversion rate equal to 120% of the closing price of the Company’s common stock on the date of issuance. In conjunction with the April 8, 2024 Note, we issued the investor a five-year warrant to purchase 30,000 shares of our common stock with an exercise price of $1.50. Accrued and unpaid interest as of March 31, 2024 was $5,976 and unamortized financing costs were $17,998.

2.	In June 2023 the Company entered into a promissory note with an entity controlled by its Chief Executive Officer, a related party. The Note is for $250,000 with $50,000 paid to the Holder on issuance for net proceeds of $200,000 and matures on December 31, 2023. The Note carries an interest of 15% per annum as interest is payable monthly in arrears with principal due at maturity. There is no penalty for early payoff. If an event of default occurs, the Note along with any outstanding and accrued interest is convertible into the Company’s Common Stock at $7.45 at the sole discretion of the issuer. On April 8, 2024 with an effective date of January 1, 2024, the Company entered into a securities purchase agreement with a related party pursuant to which the Company issued the related party a promissory note in the principal amount of $260,000 in exchange for $260,000. The maturity of the promissory note is April 30, 2024 and carries an interest rate of 20% per annum. In conjunction with the April 8, 2024 Note, we issued the investor a five-year warrant to purchase 39,000 shares of our common stock with an exercise price of $1.50. The promissory note is subordinated to the Company’s senior lender. Accrued and unpaid interest as of March 31, 2024 was $6,474 and unamortized financing costs were $ $14,279.

COMMON AND PREFERRED STOCK

3 Months Ended

Mar. 31, 2024

COMMON AND PREFERRED STOCK

COMMON AND PREFERRED STOCK

8. COMMON AND PREFERRED STOCK

Common Stock

The Company is authorized to issue up to 100,000,000 shares of Company Common Stock, par value $0.0001 per shares.

Preferred Stock

	•	The conversion price (“Conversion Price”) for the Preferred Stock is initially $10.00 per share; provided that the Conversion Price shall be reset to the lesser of $10.00 or 20% above the simple average of the volume weighted average price on the 20 trading days following 12 months after August 25, 2023; provided further that such Conversion Price shall be no greater than $10.00 and no less than $2.00 and subject to appropriate and customary adjustment.

	•	The holders of Preferred Stock shall not be entitled to vote on any matters submitted to the stockholders of the Company.

	•	From and after the date of the issuance of any shares of Preferred Stock, dividends shall accrue at the rate per annum of 12% of the original issue price for each share of Preferred Stock, prior and in preference to any declaration or payment of any other dividend (subject to appropriate adjustments).

	•	Dividends shall accrue from day to day and shall be cumulative and shall be payable within fifteen (15) business days after the end of the Company’s second quarter, which is June 30, commencing with the quarter ending June 30, 2024 to each holder of Preferred Stock as of such date.

	•	From the Closing of the Business Combination until the second anniversary of the date of the original issuance of the Preferred Stock, the Company may, at its option, pay all or part of the accruing dividends on the Preferred Stock by issuing and delivering additional shares of Preferred Stock to the holders thereof.

	•	The Company shall not declare, pay or set aside any dividends on shares of any other class or series of capital stock of the Company, unless the holders of the iCoreConnect Preferred Stock then outstanding shall first receive dividends due and owing on each outstanding share of iCoreConnect Preferred Stock.

	•	In the event of any liquidation, dissolution or winding up of the Company, the holders of shares of Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to its stockholders an amount per share equal to the greater of (i) one times the applicable original issue price, plus any accrued and unpaid dividends, and (ii) such amount as would have been payable had all shares of Preferred Stock been converted into the Company’s Common Stock pursuant to the following paragraph immediately prior to such liquidation, dissolution or winding up, before any payment shall be made to the holders of the Company’s Common Stock.

	•	Each share of Preferred Stock shall be convertible, at the option of the holder thereof, at any time and from time to time, and without the payment of additional consideration by the holder thereof, into such number of fully paid and non-assessable shares of the Company’s Common Stock as is determined by dividing the original issue price by the Conversion Price in effect at the time of conversion, subject to adjustment.

	•	After 24 months from the Closing of the Business Combination, in the event the closing share price of the Company’s Common Stock shall exceed 140% of the Conversion Price (as defined in the Merger Agreement) then in effect, then (i) each outstanding share of Preferred Stock shall automatically be converted into such number of shares of the Company’s Common Stock as is determined by dividing the original issue price by the Conversion Price in effect at the time of conversion and (ii) such shares may not be reissued by the Company, subject to adjustment. At the time of such conversion, the Company shall declare and pay all of the dividends that are accrued and unpaid as of the time of the conversion by either, at the option of the Company, (i) issuing additional Preferred Stock or (ii) paying cash.

	•	Immediately prior to any such optional conversion the Company shall pay all dividends on the Preferred Stock being converted that are accrued and unpaid as of such time by, either, at the option of the Company: (i) issuing additional Preferred Stock or (ii) paying cash.

During the three months ended March 31, 2024 the Company issued 621,500 Series A Preferred stock in conjunction with asset acquisitions of FeatherPay, Verifi Dental Limited and Teamworx LLC.

Common Stock Options

Certain employees and executives have been granted options or warrants that are compensatory in nature. A summary of option activity for the three months ended March 31, 2024 are presented below:

Options Outstanding	Number of Options		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term in Years		Aggregate Intrinsic Value

Balance Outstanding - January 1, 2024		776,328	$	3.75		8.0	$	-
Granted		3,000		1.27		9.8		-
Exercised		-		-		-		-
Forfeited		-		-		-		-
Balance Outstanding – March 31, 2024		779,328	$	3.73		7.7	$	-

Exercisable – March 31, 2024		575,235	$	3.72		7.7	$	-

Nonvested Options	Number of Options			Weighted Average Grant Date Fair Value		Weighted Average Remaining Years to Vest

Nonvested - January 1, 2024		395,072		$	3.768		8.0
Granted		3,000			1.27		9.8
Vested		(193,979	)		3.72		7.7
Forfeited		-			-		-
Nonvested – March 31, 2024		204,093		$	3.76		7.8

Restricted Common Stock Compensation

The Board approved on January 3, 2023 134,049 shares of common stock related to the Chief Executive Officer for bonus related to 2022 service with a fair value of $356,000.

On March 13, 2023 the Company’s Board of Directors approved the grant of 5,027 shares of common stock to certain board members for services related to 2018 service.

Common Stock Warrants

During the three months ending March 31, 2023, the Company issued no Common Stock Warrants.

During the three months ending March 31, 2024, the Company issued 69,000 Common Stock Warrants.

Common Stock Warrants Outstanding	Number of Warrants		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term in Years		Aggregate Intrinsic Value
Outstanding – December 31, 2023		45,129	$	2.09		4.81	$	-
Granted		69,000		1.36		4.76		-
Exercised		-		-		-		-
Cancelled		-		-		-		-
Outstanding – March 31, 2024		114,129	$	1.65		4.68	$	-

Preferred Stock Warrants

$2.00 Preferred Stock Warrants Outstanding	Number of Warrants		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term in Years		Aggregate Intrinsic Value
Outstanding – December 31, 2023		425,800	$	2.00		9.7	$	-
Granted		-		-		-		-
Exercised		-		-		-		-
Expired		-		-		-		-
Outstanding – March 31, 2024		425,800	$	2.00		9.4	$	-

$11.50 Preferred Stock Warrants Outstanding	Number of Warrants		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term in Years		Aggregate Intrinsic Value
Outstanding – December 31, 2023		10,122,313	$	11.50		9.7	$	-
Granted		-		-		-		-
Exercised		-		-		-		-
Expired		-		-		-		-
Outstanding – March 31, 2024		10,122,313	$	11.50		9.4	$	-

$15.00 Preferred Stock Warrants Outstanding	Number of Warrants		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term in Years		Aggregate Intrinsic Value
Outstanding – December 31, 2023		1,000,000	$	15.00		9.7	$	-
Granted		-		-		-		-
Exercised		-		-		-		-
Expired		-		-		-		-
Outstanding – March 31, 2024		1,000,000	$	15.00		9.4	$	-

Equity Line of Credit

This line was cancelled in February 2024 and the Company expensed deferred costs of $1,008,376 related to this transaction which were recorded as financing costs.

COMMITMENTS AND CONTINGENCIES

3 Months Ended

Mar. 31, 2024

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES

9. COMMITMENTS AND CONTINGENCIES

(A) LEASE COMMITMENTS

As of March 31, 2024, undiscounted future lease obligations for the office spaces are as follows:

Lease Commitments
Less than 1 year		1-3 years		3-5 years		Total
$	361,424	$	1,019,651	$	41,386	$	1,422,461

Undiscounted minimum lease commitments	$	1,422,461
Present value adjustment using incremental borrowing rate		(295,742	)
Lease liabilities	$	1,126,719

(B) LITIGATION

(C) COMPENSATION

CONCENTRATION OF CREDIT RISK

3 Months Ended

Mar. 31, 2024

CONCENTRATION OF CREDIT RISK

CONCENTRATION OF CREDIT RISK

10. CONCENTRATION OF CREDIT RISK

SEGMENT INFORMATION

3 Months Ended

Mar. 31, 2024

SEGMENT INFORMATION

SEGMENT INFORMATION

11. SEGMENT INFORMATION

Revenue types were as follows:

	For the Three Months Ended March 31
	2024		%			2023		%			% Change
Revenue:
Subscription software and services	$	2,595,050		95	%	$	1,703,815		93	%		52	%

Professional services and other		128,313		5	%		136,556		7	%		(6)	%

Total revenue	$	2,723,363		100	%	$	1,840,371		100	%		48	%

BUSINESS COMBINATIONS

3 Months Ended

Mar. 31, 2024

BUSINESS COMBINATIONS

BUSINESS COMBINATIONS

12. BUSINESS COMBINATIONS

Ally Commerce, Inc dba FeatherPay (“FeatherPay”)

Teamworx LLC (“Teamworx”)

Verifi Dental Limited (“Verifi”)

The following table summarizes the consideration paid and the fair value of the assets acquired and liabilities assumed as of the dates detailed in the table:

	FeatherPay		Verifi Dental		Teamworx
Consideration Paid:	January 1, 2024		January 1, 2024		January 1, 2024
Cash	$	500,000	$	370,000	$	-
Note payable		-		-		125,000
Common stock		-		-		-
Series A preferred stock		4,800,000		840,000		575,000
	$	5,300,000	$	1,210,000	$	700,000

Fair values of identifiable assets acquired and liabilities assumed:

Assets acquired:
Cash	$	-	$	871	$	12,752
Accounts receivable		959		54,259
Customer relationships		-
Acquired technology		5,299,041		1,154,870		678,548
Deferred revenue						8,700
Total assets acquired		5,300,000		1,210,000		700,000

Net assets acquired	$	5,300,000	$	1,210,000	$	700,000

SUBSEQUENT EVENTS

3 Months Ended

Mar. 31, 2024

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS

13. SUBSEQUENT EVENTS

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

3 Months Ended

Mar. 31, 2024

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

Accounts Receivable and Allowance For Doubtful Accounts

Software Development Costs and Acquired Software

Long-Lived Assets and Goodwill

Revenue Recognition

We have 6 primary sources of revenue as of March 31, 2024 and December 31, 2023:

We have 6 primary sources of revenue

	1.	Electronic Prescription Software
	2.	Insurance Verifications
	3.	ICD-10 Medical Coding Software
	4.	Encrypted and HIPAA Compliant Secure email
	5.	Analytics
	6.	MSaaS software

1) Electronic Prescription software services are provided on an annual subscription basis using the software as a service (‘SaaS’) model with revenue recognized ratably over the contract term.

2). Insurance verification services are provided on an annual subscription basis using SaaS model with revenue recognized ratably over the contract term.

3) ICD-10 Medical Coding services are provided on an annual subscription basis using the software as a SaaS model with revenues recognized ratably over the contract term.

4) Encrypted and HIPAA compliant and secure email services are provided on an annual subscription basis using the SaaS model with revenues recognized ratably over the contract term.

6) MSaaS software services are provided on an annual subscription basis using the software as a service (‘SaaS’) model with revenue recognized ratably over the contract term.

Advertising Costs

Accounting for Derivative Instruments

Financial Instruments With Down Round Features

Income Taxes

Net Loss Per Share

Beneficial Conversion Features and Warrants

Leases

Business Combinations

Allowance for Credit Losses

Recently Issued Accounting Pronouncements

Adopted

Not Yet Adopted

BUSINESS COMBINATION AND RECAPITALIZATION (Tables)

3 Months Ended

Mar. 31, 2024

BUSINESS COMBINATION AND RECAPITALIZATION

Schedule of consummation of the Business Combination

	Common Stock			Preferred Stock

Common stock of FGMC outstanding prior to business combination		8,050,000			-
Less: Redemptions of FGMC common stock		(6,460,059	)		-
Common stock held by former FGMC shareholders		1,589,941			-
FGMC sponsor shares		1,692,374			-
Underwriter shares		40,250			-
Sponsor shares transferred for services		2,000			-
Sponsor shares transferred for non-redemption		373,126			-
Shares issued related to extension note		84,500			-
Total FGMC common shares outstanding prior to conversion to preferred stock		3,782,191			-
Conversion of existing FGMC common stockholders to new preferred stock		(3,782,191	)		3,782,191
Shares issued to Old iCore stockholders for purchase consideration		8,095,706			-
Total		8,095,706			3,782,191

Schedule of reconcile of statement of changes in stockholder's equity

	Amount
Cash - FGMC trust (net of redemptions)	$	17,002,897
Cash transferred to Forward Purchase Agreement		(12,569,810	)
Gross proceeds		4,433,087
Less: FGMC and Old iCore transaction costs paid		(4,433,087	)
Effect of Business Combination, net of redemptions and transaction costs	$	-

Schedule of warrants were converted into Preferred Stock warrants

Holder	Number of Warrants		Strike Price
Underwriter		600,000	$	2.00
Sponsor and Investors		10,122,313	$	11.50
Sponsor		1,000,000	$	15.00

INTANGIBLE ASSETS AND GOODWILL (Tables)

3 Months Ended

Mar. 31, 2024

INTANGIBLE ASSETS AND GOODWILL

Schedule of carrying amounts and accumulated amortization

	Gross Carrying Amount		Impairment			Accumulated Amortization			Net Carrying Amount
Definite-lived intangible assets:
Capitalized software	$	3,741,511	$	-		$	(2,838,099	)	$	903,412
Customer relationships		5,272,578		(105,676	)		(2,186,490	)		2,980,412
Acquired technology		1,527,186		-			(1,527,186	)		-
Total definite-lived intangible assets at December 31, 2023		10,541,275		(105,676	)		(6,551,775	)		3,883,824

Capitalized software		4,075,948		-			(2,950,580	)		1,125,368
Customer relationships		5,166,903		-			(2,436,983	)		2,729,920
Acquired technology		7,148,083		-			(356,055	)		6,792,028
Total definite-lived intangible assets at March 31, 2024	$	16,390,934		-		$	(5,743,618	)	$	10,647,316

Schedule of Goodwill

	Total
Balance at December 31, 2023	$	1,484,966
2024 acquisitions		-
Balance at March 31, 2024	$	1,484,966

NOTES PAYABLE (Tables)

3 Months Ended

Mar. 31, 2024

NOTES PAYABLE

Schedule of Notes Payable

		March 31,			December 31,
		2024			2023
(2)	Note bearing interest at 18% due October 1, 2026		25,325			27,540
(3)	Secured Promissory Note bearing interest at 17.5% due February 28, 2026		1,753,761			1,988,793
(4)	Promissory Note bearing interest at 12%, due October 31, 2023		-			38,609
(5)	Convertible Note bearing interest at 12% due May 13, 2024		369,560			388,380
(6)	Convertible Note bearing interest at 12%, due October 31, 2024		564,513			569,391
(6)	Convertible Note bearing interest at 12%, due December 18, 2024		572,407			574,961
(7)	Convertible Note bearing interest at 12%, due December 19, 2024		79,813			80,722
(8)	Convertible Note bearing interest at 12%, due December 19, 2024		79,813			80,509
(5)	Convertible Note bearing interest at 12%, due December 28, 2024		125,092			114,781
(1)	Convertible Note bearing interest at 12%, due June 1, 2024		527,603			473,743
(9)	Promissory Note bearing interest at 15%, due December 26, 2024		2,074,795			2,000,000
(21)	Promissory Note bearing interest at 12%, due May 3, 2024		127,425			-
(11)	Convertible Note bearing interest at 12%, due February 1, 2025		57,629			-
(12)	Convertible Note bearing interest at 12%, due February 1, 2025		5,763			-
(13)	Convertible Note bearing interest at 16%, due February 26, 2025		404,225			-
(13)	Convertible Note bearing interest at 16%, due February 26, 2025		1,280,047			-
	Total notes payable		8,047,771			6,337,429
	Less: Unamortized debt discounts		(104,167	)		-
	Less: unamortized financing costs		(359,569	)		(196,837	)
	Total notes payable, net of financing costs		7,584,035			6,140,592
	Less current maturities		(6,388,603	)		(4,720,455	)
	Total Long-Term Debt	$	1,195,432		$	1,420,137

RELATED PARTY TRANSACTIONS (Tables)

3 Months Ended

Mar. 31, 2024

RELATED PARTY TRANSACTIONS

Schedule of Related Party Transactions

		March 31,			December 31,
		2023			2023
(2)	Related Party Promissory Note bearing interest at 18%, due December 31, 2023	$	-		$	249,855
(1)	Related Party Promissory Note bearing interest at 12%, due December 31, 2023		-			225,797
(1)	Related Party Convertible Promissory Note bearing interest at 12%, due May 26, 2024		113,708			96,753
(2)	Related Party Promissory Note bearing interest at 20%, due April 30, 2024		280,753			-
(1)	Related Party Convertible Promissory Note bearing interest at 12%, due April 30, 2024		223,975			-
	Total notes payable		618,436			572,405
	Less: Unamortized debt discounts		-			-
	Less: unamortized financing costs		(46,309	)		(21,431	)
	Total notes payable, net of financing costs		572,127			550,974
	Less current maturities		(572,127	)		(550,974	)
	Total Long-Term Debt	$	-		$	-

COMMON AND PREFERRED STOCK (Tables)

3 Months Ended

Mar. 31, 2024

COMMON AND PREFERRED STOCK

Summary of Stock Option Activity

Options Outstanding	Number of Options		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term in Years		Aggregate Intrinsic Value

Balance Outstanding - January 1, 2024		776,328	$	3.75		8.0	$	-
Granted		3,000		1.27		9.8		-
Exercised		-		-		-		-
Forfeited		-		-		-		-
Balance Outstanding – March 31, 2024		779,328	$	3.73		7.7	$	-

Exercisable – March 31, 2024		575,235	$	3.72		7.7	$	-

Nonvested Options	Number of Options			Weighted Average Grant Date Fair Value		Weighted Average Remaining Years to Vest

Nonvested - January 1, 2024		395,072		$	3.768		8.0
Granted		3,000			1.27		9.8
Vested		(193,979	)		3.72		7.7
Forfeited		-			-		-
Nonvested – March 31, 2024		204,093		$	3.76		7.8

Schedule of warrants outstanding

Common Stock Warrants Outstanding	Number of Warrants		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term in Years		Aggregate Intrinsic Value
Outstanding – December 31, 2023		45,129	$	2.09		4.81	$	-
Granted		69,000		1.36		4.76		-
Exercised		-		-		-		-
Cancelled		-		-		-		-
Outstanding – March 31, 2024		114,129	$	1.65		4.68	$	-

$2.00 Preferred Stock Warrants Outstanding	Number of Warrants		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term in Years		Aggregate Intrinsic Value
Outstanding – December 31, 2023		425,800	$	2.00		9.7	$	-
Granted		-		-		-		-
Exercised		-		-		-		-
Expired		-		-		-		-
Outstanding – March 31, 2024		425,800	$	2.00		9.4	$	-

$11.50 Preferred Stock Warrants Outstanding	Number of Warrants		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term in Years		Aggregate Intrinsic Value
Outstanding – December 31, 2023		10,122,313	$	11.50		9.7	$	-
Granted		-		-		-		-
Exercised		-		-		-		-
Expired		-		-		-		-
Outstanding – March 31, 2024		10,122,313	$	11.50		9.4	$	-

$15.00 Preferred Stock Warrants Outstanding	Number of Warrants		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term in Years		Aggregate Intrinsic Value
Outstanding – December 31, 2023		1,000,000	$	15.00		9.7	$	-
Granted		-		-		-		-
Exercised		-		-		-		-
Expired		-		-		-		-
Outstanding – March 31, 2024		1,000,000	$	15.00		9.4	$	-

COMMITMENTS AND CONTINGENCIES (Tables)

3 Months Ended

Mar. 31, 2024

COMMITMENTS AND CONTINGENCIES

Schedule of undiscounted future lease obligations

Lease Commitments
Less than 1 year		1-3 years		3-5 years		Total
$	361,424	$	1,019,651	$	41,386	$	1,422,461

Schedule of Undiscounted minimum lease commitments

Undiscounted minimum lease commitments	$	1,422,461
Present value adjustment using incremental borrowing rate		(295,742	)
Lease liabilities	$	1,126,719

SEGMENT INFORMATION (Tables)

3 Months Ended

Mar. 31, 2024

SEGMENT INFORMATION

Revenue Segment

	For the Three Months Ended March 31
	2024		%			2023		%			% Change
Revenue:
Subscription software and services	$	2,595,050		95	%	$	1,703,815		93	%		52	%

Professional services and other		128,313		5	%		136,556		7	%		(6)	%

Total revenue	$	2,723,363		100	%	$	1,840,371		100	%		48	%

BUSINESS COMBINATIONS (Tables)

12 Months Ended

Dec. 31, 2022

BUSINESS COMBINATIONS

Schedule of fair value of the assets acquired and liabilities

	FeatherPay		Verifi Dental		Teamworx
Consideration Paid:	January 1, 2024		January 1, 2024		January 1, 2024
Cash	$	500,000	$	370,000	$	-
Note payable		-		-		125,000
Common stock		-		-		-
Series A preferred stock		4,800,000		840,000		575,000
	$	5,300,000	$	1,210,000	$	700,000

Fair values of identifiable assets acquired and liabilities assumed:

Assets acquired:
Cash	$	-	$	871	$	12,752
Accounts receivable		959		54,259
Customer relationships		-
Acquired technology		5,299,041		1,154,870		678,548
Deferred revenue						8,700
Total assets acquired		5,300,000		1,210,000		700,000

Net assets acquired	$	5,300,000	$	1,210,000	$	700,000

NATURE OF OPERATIONS (Details Narrative) - USD ($)	3 Months Ended
NATURE OF OPERATIONS (Details Narrative) - USD ($)	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
NATURE OF OPERATIONS
Operating loss	$ 3,042,185	$ 1,351,058
Working capital deficit	(10,906,674)
Accumulated deficit	$ (120,209,729)		$ (115,038,758)

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Allowance for doubtful accounts	$ 37,097	$ 102,061
Fair value and impairment	105,676
Advertising Costs	208,085	125,048
Recurring revenues	2,595,050	1,703,815
Non recurring revenues	$ 128,313	$ 136,556

BUSINESS COMBINATION AND RECAPITALIZATION (Details) - shares	Mar. 31, 2024	Dec. 31, 2023
Common stock of FGMC outstanding prior to business combination shares	10,240,398	10,068,477
Common Stock issued	10,240,398	10,068,477
Preferred Stock issued	4,376,709	3,755,209
Preferred Share [Member]
Conversion of existing FGMC common stockholders to new preferred stock	3,782,191
Preferred Stock issued	3,782,191
Common Share [Member]
Common stock of FGMC outstanding prior to business combination shares	8,050,000
Less: Redemptions of FGMC common stock	(6,460,059)
Common stock held by former FGMC shareholders	1,589,941
FGMC sponsor shares	1,692,374
Underwriter shares	40,250
Sponsor shares transferred for services	2,000
Sponsor shares transferred for non-redemption	373,126
Shares issued related to extension note	84,500
Total FGMC common shares outstanding prior to conversion to preferred stock	3,782,191
Conversion of existing FGMC common stockholders to new preferred stock	(3,782,191)
Shares issued to Old iCore stockholders for purchase consideration	8,095,706
Common Stock issued	8,095,706

BUSINESS COMBINATION AND RECAPITALIZATION (Details 1)	Mar. 31, 2024 USD ($)
BUSINESS COMBINATION AND RECAPITALIZATION
Cash - FGMC trust (net of redemptions)	$ 17,002,897
Cash transferred to Forward Purchase Agreement	(12,569,810)
Gross proceeds	4,433,087
Less: FGMC and Old iCore transaction costs paid	(4,433,087)
Effect of Business Combination, net of redemptions and transaction costs	$ 0

BUSINESS COMBINATION AND RECAPITALIZATION (Details 2)	Mar. 31, 2024 $ / shares shares
Sponsor And Investors Member [Member]
Number of Warrants \| shares	10,122,313
Strike Price \| $ / shares	$ 11.50
Sponsor [Member]
Number of Warrants \| shares	1,000,000
Strike Price \| $ / shares	$ 15.00
Underwriter [Member]
Number of Warrants \| shares	600,000
Strike Price \| $ / shares	$ 2.00

BUSINESS COMBINATION AND RECAPITALIZATION (Details Narrative) - $ / shares	Mar. 31, 2024	Dec. 31, 2023	Aug. 25, 2023	Mar. 31, 2023
BUSINESS COMBINATION AND RECAPITALIZATION
Common stock, par value	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001
Common Stock, shares authorized	100,000,000	100,000,000	100,000,000	100,000,000
Preferred stock, shares authorized	40,000,000	40,000,000	40,000,000	40,000,000
Preferred stock, par value	$ 0.0001	$ 0.0001	$ 0.0001
Capital stock Authorized			140,000,000

INTANGIBLE ASSETS AND GOODWILL (Details) - USD ($)	3 Months Ended	12 Months Ended
INTANGIBLE ASSETS AND GOODWILL (Details) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Gross carrying amount	$ 16,390,934	$ 10,541,275
Impairment	0	(105,676)
Accumulated amortization	(5,743,618)	(6,551,775)
Net carrying amount	10,647,316	3,883,824
Capitalized Software [Member]
Gross carrying amount	4,075,948	3,741,511
Impairment	0	0
Accumulated amortization	(2,950,580)	(2,838,099)
Net carrying amount	1,125,368	903,412
Customer Relationships [Member]
Gross carrying amount	5,166,903	5,272,578
Impairment	0	(105,676)
Accumulated amortization	(2,436,983)	(2,186,490)
Net carrying amount	2,729,920	2,980,412
Acquired Technology [Member]
Gross carrying amount	7,148,083	1,527,186
Impairment	0	0
Accumulated amortization	(356,055)	(1,527,186)
Net carrying amount	$ 6,792,028	$ 0

INTANGIBLE ASSETS AND GOODWILL (Details 1)	3 Months Ended
INTANGIBLE ASSETS AND GOODWILL (Details 1)	Mar. 31, 2024 USD ($)
INTANGIBLE ASSETS AND GOODWILL
Balance, beginning	$ 1,484,966
2024 Acquisitions	0
Balance, ending	$ 1,484,966

INTANGIBLE ASSETS AND GOODWILL (Details Narrative) - USD ($)	1 Months Ended		3 Months Ended		12 Months Ended
	Jan. 31, 2024	Sep. 30, 2023	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Amortization expense of intangible assets			$ 719,028	$ 283,176	$ 283,176
Customer Relationships [Member]
Finite-Lived Intangible Asset		$ 1,559,145
Acquired Technology [Member]
Finite-Lived Intangible Asset	$ 7,148,083
Capitalized Computer Software	$ 334,437

FORWARD PURCHASE AGREEMENT (Details Narrative)	3 Months Ended
FORWARD PURCHASE AGREEMENT (Details Narrative)	Mar. 31, 2024 $ / shares shares
FORWARD PURCHASE AGREEMENT
Commitment Shares issued \| shares	100,000
Redemption Price \| $ / shares	$ 10.69

NOTES PAYABLE (Details) - USD ($)	3 Months Ended
NOTES PAYABLE (Details) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Unamortized debt discounts	$ (104,167)	$ 0
unamortized financing costs	(359,569)	(196,837)
Total notes payable, net of financing costs	7,584,035	6,140,592
Less current maturities	(6,388,603)	(4,720,455)
Total Long-Term Debt	1,195,432	1,420,137
Total notes payable	8,047,771	6,337,429
Convertible Note 10 [Member]
Long-term debt, gross	$ 5,763	0
Interest rate	12.00%
Due date	Feb. 01, 2025
Convertible Note 1 [Member]
Long-term debt, gross	$ 369,560	388,380
Interest rate	12.00%
Due date	May 13, 2024
Convertible Note 3 [Member]
Long-term debt, gross	$ 572,407	574,961
Interest rate	12.00%
Due date	Dec. 18, 2024
Convertible Note 4 [Member]
Long-term debt, gross	$ 79,813	80,722
Interest rate	12.00%
Due date	Dec. 19, 2024
Convertible Note 6 [Member
Long-term debt, gross	$ 125,092	114,781
Interest rate	12.00%
Due date	Dec. 28, 2024
Convertible Note 8 [Member]
Long-term debt, gross	$ 527,603	473,743
Interest rate	12.00%
Due date	Jun. 01, 2024
Convertible Note 9 [Member]
Long-term debt, gross	$ 57,629	0
Interest rate	12.00%
Due date	Feb. 01, 2025
Convertible Note 12 [Member]
Long-term debt, gross	$ 1,280,047	0
Interest rate	16.00%
Due date	Feb. 26, 2025
Note Bearing 1 [Member]
Long-term debt, gross	$ 25,325	27,540
Interest rate	18.00%
Due date	Oct. 01, 2026
Secured Promissory Note [Member]
Long-term debt, gross	$ 1,753,761	1,988,793
Interest rate	17.50%
Due date	Feb. 28, 2026
Promissory Note 1 [Member]
Long-term debt, gross	$ 0	38,609
Interest rate	12.00%
Due date	Oct. 31, 2023
Promissory Note 2 [Member]
Long-term debt, gross	$ 2,074,795	2,000,000
Interest rate	15.00%
Due date	Dec. 26, 2024
Promissory Note 3 [Member
Long-term debt, gross	$ 127,425	0
Interest rate	12.00%
Due date	May 03, 2024
Convertible Note 2 [Member
Long-term debt, gross	$ 564,513	569,391
Interest rate	12.00%
Due date	October 31, 2024
Convertible Note 5 [Member]
Long-term debt, gross	$ 79,813	80,509
Interest rate	12.00%
Due date	Dec. 19, 2024
Convertible Note 7 [Member]
Long-term debt, gross	$ 404,225	$ 0
Interest rate	16.00%
Due date	Feb. 26, 2025

NOTES PAYABLE (Details Narrative) - USD ($)					1 Months Ended					3 Months Ended
NOTES PAYABLE (Details Narrative) - USD ($)	Feb. 09, 2024	Feb. 02, 2024	Feb. 28, 2022	Nov. 30, 2021	Feb. 26, 2024	Dec. 31, 2023	Dec. 28, 2023	Oct. 31, 2023	Sep. 30, 2023	Mar. 31, 2024	Mar. 31, 2023	Jan. 02, 2024
Interest Rate									12.00%
Interest									$ 38,609	$ 226,467	$ 257,913
Proceed from advance									$ 1,200,000
Payments Of Principal And Interest										1,302,697	$ 80,063
Secured Promissory Note Payable [Member]
Convertible Promissory Note			$ 2,000,000
Accrued interest due										$ 500,000
Exchange Received			$ 1,970,000
Interest Rate			17.50%			12.00%
Principal Amount						$ 70,000
Description of Maturity renegotiated						interest rate of 12% per annum and is initially convertible into Company common stock at a conversion rate equal to 120% of the closing price of the Company’s common stock on the date of issuance which was $1.69 or $2.03 for the share price of conversion
Maintaining Minimum Cash Balance			$ 150,000
Outstanding interest and fees			$ 300,000
Convertible Promissory Note [Member]
Outstanding warrants								24,500
Convertible Promissory Note		$ 5,000			$ 1,375,000		$ 100,000	$ 350,000
Exercisable price								$ 2.04
Convertible shares of Common Stock					85,174
Interest Rate		12.00%				12.00%	12.00%	12.00%
Principal Amount					$ 2,375,000	$ 500,000		$ 500,000
Common Stock at fixed conversion price								$ 1.85
Common Stock Conversion Percentage						120.00%
Exercise price, per share										$ 1.69
Exercise price one										$ 2.03
Description of Maturity renegotiated					(i) the Registration Statement (as described below) is effective; and (ii) the Shareholder Approval (as described below) has been obtained. The Notes will mature 12 months from their respective issuance date (the “Maturity Date”), unless earlier converted. Commencing on the six-month anniversary of the issue date, the Company will be required to make monthly amortization payments pursuant to the Note of approximately 1/6th of the principal amount of the Note per month (the “Amortization Payments”). The Notes will be the Company’s unsecured obligations and equal in right of payment with all of our other indebtedness and other indebtedness of any of our subsidiaries. The Notes were issued with an original issue discount of 10.0% per annum, and will not accrue additional interest during the term; provided that the interest rate of the Notes will automatically increase to 16% per annum (the “Default Rate”) upon the occurrence and continuance of an event of default. Each holder of Notes may convert all, or any part, of the outstanding Notes, at any time at such holder’s option, into shares of the Company’s common stock at an initial “Conversion Price” of $1.848 per share	common stock on the date of issuance which was $2.31 or $2.77 for the share price of conversion	Company common stock at a conversion rate equal to 120% of the closing price of the Company’s common stock on the date of issuance which was $1.31 or $1.57 for the share price of conversion	The maturity of the Convertible Promissory Note is October 31, 2024 and carries an interest rate of 12% per annum and is initially convertible into Company common stock at a conversion rate equal to 120% of the closing price of the Company’s common stock on the date of issuance which was $1.58 or $1.90
Convertible Promissory Note one		$ 5,000
Finance Agreement Payment				$ 40,071
Maturity date				60 years
Payments Of Principal And Interest				$ 791
One [Member]
Outstanding warrants	473,743					2,000,000				2,000,000		125,000
Proceed from convertible promissory notes	$ 473,743	$ 50,000			$ 1,250,000
Interest Rate	12.00%	12.00%				15.00%
Conversion of account payable in amount		$ 50,000				$ 2,000,000
Quarterly installments payment for consulting services						$ 200,000
Principal Amount					$ 1,100,000

RELATED PARTY TRANSACTIONS (Details) - USD ($)	3 Months Ended
RELATED PARTY TRANSACTIONS (Details) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Less: Unamortized debt discounts	$ 104,167	$ 0
unamortized financing costs	(359,569)	(196,837)
Total notes payable, net of financing costs	7,584,035	6,140,592
Less current maturities	(6,388,603)	(4,720,455)
Total Long-Term Debt	1,195,432	1,420,137
Promissory Note Member
Long-term debt, gross	618,436	572,405
Less: Unamortized debt discounts	0	0
unamortized financing costs	(46,309)	(21,431)
Total notes payable, net of financing costs	572,127	550,974
Less current maturities		(550,974)
Total Long-Term Debt	0	0
Promissory Note bearing 1 Member
Long-term debt, gross	$ 0	225,797
Interest rate	12.00%
Due dates	December 31, 2023
Promissory Note bearing 2 Member
Long-term debt, gross	$ 0	249,855
Interest rate	18.00%
Due dates	December 31, 2023
Promissory Note bearing 3 Member
Long-term debt, gross	$ 113,708	96,753
Interest rate	12.00%
Due dates	May 26, 2024
Promissory Note bearing 4 Member
Long-term debt, gross	$ 280,753	0
Interest rate	20.00%
Due dates	April 30, 2024
Promissory Note bearing 5 Member
Long-term debt, gross	$ 223,975	$ 0
Interest rate	12.00%
Due dates	April 30, 2024

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)		1 Months Ended		3 Months Ended
	Apr. 08, 2024	Oct. 31, 2023	Jun. 30, 2023	Mar. 31, 2024
Unsecured Debt [Member]
Accrued and unpaid interest				$ 6,474
Unamortized financing costs				$ 14,279
Chief Operating Officer [Member]
Promissory Note		$ 200,000
Unsecured promissory note amount			$ 250,000
Unsecured promissory note paid to holder			50,000
Net proceeds from issue of unsecured promissory note paid to holder			$ 200,000
Issue of convertible promissory note number of common stock to investor		6,629
Interest rate	20.00%	12.00%	15.00%	12.00%
Exercise Price	$ 1.50	$ 2.16		$ 2.15
Closing price		120.00%		120.00%
Principal amount	$ 260,000	$ 94,685		$ 200,000
Conversion rates		$ 1.80
Accrued and unpaid interest				5,976
Unamortized financing costs				$ 17,998
Issue of warrant to purchase of common stock	39,000	14,000		30,000
Issue of warrant to purchase of common stock period	5 years	5 years		5 years
Notes and accrued interest conversion rate			$ 7.45

COMMON AND PREFERRED STOCK (Details)	3 Months Ended
COMMON AND PREFERRED STOCK (Details)	Mar. 31, 2024 $ / shares shares
Options Outstanding
Number of Options Outstanding, Beginning \| shares	776,328
Number of Options granted \| shares	3,000
Number of Options Outstanding, Ending \| shares	779,328
Number of Options Outstanding, Exercisable Ending \| shares	575,235
Weighted Average Exercise Price, Beginning	$ 3.75
Weighted Average Exercise Price, Granted	1.27
Weighted Average Exercise Price, Exercised	0
Weighted Average Exercise Price, Forfeited	0
Weighted Average Exercise Price, Ending	3.73
Weighted Average Exercise Price, Exercisable	$ 3.72
Weighted Average Remaining Contractual Term in Years, Beginning	8 years
Weighted Average Remaining Contractual Term in Years, granted	9 years 9 months 18 days
Weighted Average Remaining Contractual Term in Years, Ending	7 years 8 months 12 days
Weighted Average Remaining Contractual Term in Years, Exercisable Ending	7 years 8 months 12 days
Nonvested Options
Number of Options Nonvested, Beginning \| shares	395,072
Number of Options Nonvested, Granted \| shares	3,000
Number of Options Nonvested, Ending \| shares	204,093
Weighted Average grant date Fair Value Nonvested, Beginning	$ 3.76
Weighted Average grant date Fair Value Nonvested, Vested	1.27
Weighted Average grant date Fair Value Nonvested, Granted	3.72
Weighted Average grant date Fair Value Nonvested, Forfeited	0
Weighted Average grant date Fair Value Nonvested, Ending	$ 3.76
Weighted Average Remaining Years to vest Nonvested, Beginning	8 years
Weighted Average Remaining Years to vest Nonvested, Vested	7 years 8 months 12 days
Weighted Average Remaining Years to vest Nonvested, Granted	9 years 9 months 18 days
Weighted Average Remaining Years to vest Nonvested, Ending	7 years 9 months 18 days

COMMON AND PREFERRED STOCK (Details 1)	3 Months Ended
COMMON AND PREFERRED STOCK (Details 1)	Mar. 31, 2024 USD ($) $ / shares shares
COMMON AND PREFERRED STOCK
Number of Warrants Outstanding, Beginning \| shares	45,129
Number of Warrants,Granted \| shares	69,000
Number of Warrants Outstanding, Ending \| shares	114,129
Weighted Average Exercise Price of Warrants, Beginning	$ 2.09
Weighted Average Exercise Price of Warrants, Exercised	0
Weighted Average Exercise Price of Warrants, Cancelled	0
Weighted Average Exercise Price of Warrants, Granted	1.36
Weighted Average Exercise Price of Warrants, Ending	$ 1.65
Weighted Average Remaining Life of Warrants in Years, Beginning	4 years 9 months 21 days
Weighted Average Remaining Life of Warrants in Years,Granted	4 years 9 months 3 days
Weighted Average Remaining Life of Warrants in Years, Ending	4 years 8 months 4 days
Aggregate Intrinsic Value of Warrants, Beginning \| $	$ 0
Aggregate Intrinsic Value of Warrants, Ending \| $	$ 0

COMMON AND PREFERRED STOCK (Details 2)	3 Months Ended
COMMON AND PREFERRED STOCK (Details 2)	Mar. 31, 2024 $ / shares shares
COMMON AND PREFERRED STOCK
One Number of Warrants Outstanding, Beginning \| shares	425,800
One Number of Warrants Outstanding, Ending \| shares	425,800
One Weighted Average Exercise Price of Warrants, Beginning	$ 2.00
One Weighted Average Exercise Price of Warrants, Granted	0
One Weighted Average Exercise Price of Warrants, Exercised	0
One Weighted Average Exercise Price of Warrants, expired	0
One Weighted Average Exercise Price of Warrants, Ending	$ 2.00
One Weighted Average Remaining Life of Warrants in Years, Beginning	9 years 8 months 12 days
One Weighted Average Remaining Life of Warrants in Years, Ending	9 years 4 months 24 days

COMMON AND PREFERRED STOCK (Details 3)	3 Months Ended
COMMON AND PREFERRED STOCK (Details 3)	Mar. 31, 2024 $ / shares shares
COMMON AND PREFERRED STOCK
Two Number of Warrants Outstanding, Ending \| shares	10,122,313
Two Weighted Average Exercise Price of Warrants, Beginning	$ 11.50
Two Weighted Average Exercise Price of Warrants, Granted	0
Two Weighted Average Exercise Price of Warrants, Exercised	0
Two Weighted Average Exercise Price of Warrants, expired	0
Two Weighted Average Exercise Price of Warrants, Ending	$ 11.50
One Weighted Average Remaining Life of Warrants in Years, Beginning	9 years 8 months 12 days
Two Preferred Stock Warrants Outstanding, Beginning \| shares	10,122,313
One Weighted Average Remaining Life of Warrants in Years, Ending	9 years 4 months 24 days

COMMON AND PREFERRED STOCK (Details 4)	3 Months Ended
COMMON AND PREFERRED STOCK (Details 4)	Mar. 31, 2024 $ / shares shares
COMMON AND PREFERRED STOCK
Three Number of Warrants Outstanding, Ending \| shares	1,000,000
Three Weighted Average Exercise Price of Warrants, Beginning	$ 15.00
Three Weighted Average Exercise Price of Warrants, Granted	0
Three Weighted Average Exercise Price of Warrants, Exercised	0
Three Weighted Average Exercise Price of Warrants, expired	0
Three Weighted Average Exercise Price of Warrants, Ending	$ 15.00
Three Weighted Average Remaining Life of Warrants in Years, Beginning	9 years 8 months 12 days
Three Weighted Average Remaining Life of Warrants in Years, Ending	9 years 4 months 24 days
Three Preferred Stock Warrants Outstanding, Beginning \| shares	1,000,000

COMMON AND PREFERRED STOCK (Details Narrative) - USD ($)		1 Months Ended	3 Months Ended
	Sep. 12, 2023	Apr. 30, 2023	Mar. 31, 2024	Mar. 31, 2023	Jun. 30, 2022	Dec. 31, 2023	Aug. 25, 2023	Mar. 13, 2023	Jan. 03, 2023
Common Stock Shares authorized			100,000,000	100,000,000		100,000,000	100,000,000
Common Stock, par value			$ 0.0001	$ 0.0001		$ 0.0001	$ 0.0001
Preferred Stock Shares authorized			40,000,000	40,000,000		40,000,000	40,000,000
Preferred Stock Shares issued			4,376,709			3,755,209
Common stock issued, shares			291,259
Common stock issued, value			$ 600,000		$ 45,000
Restricted Stock Compensation			$ 105,000	$ 0
Additional warrants to be issued			69,000
Financing costs			$ 1,008,376
Common Stock Shares Issued For Cash, Value			540,000
Shares of common stock on the conversion of debt			$ 85,174
Common stock related to stock based compensation			86,747
Committee [Member]
Additional compensation		$ 5,000
Chair of a Committee [Member]
Additional compensation		5,000
Board Chair [Member]
Additional compensation		20,000
Restricted Stock Compensation [Member]
Restricted common stock issued for service, shares			2,425,000
Compensation		$ 60,000
Restricted Stock Compensation [Member] \| 2020 Service [Member] \| Chief Executive Officers [Member]
Restricted shares of common stock issued for bonus, value				$ 356,000
Restricted Shares Of Common Stock Issued For Bonus, Shares								5,027
Arena Business Solutions Global SPC II [Member]
Purchase of Common stock	40,000,000
Chief Executive Officer [Member]
Restricted Shares Of Common Stock Issued For Bonus, Shares									134,049
Series A Preferred Stock [Member]
Preferred Stock Shares authorized			40,000,000
Preferred Stock Shares per value			$ 0.0001
Conversion Price			$ 10.00
Accrued Intrest rate			12.00%
Preferred Stock Shares issued			621,500

COMMITMENTS AND CONTINGENCIES (Details)	Mar. 31, 2024 USD ($)
Lease Commitments	$ 1,422,461
Less Than 1 Year [Member]
Lease Commitments	361,424
1-3 years [Member]
Lease Commitments	1,019,651
3-5 years [Member]
Lease Commitments	$ 41,386

COMMITMENTS AND CONTINGENCIES (Details 1) - Lease [Member]	Mar. 31, 2024 USD ($)
Undiscounted Minimum Lease Commitments	$ 1,422,461
Present Value Adjustment Using Incremental Borrowing Rate	(295,742)
Lease Liabilities	$ 1,126,719

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)		1 Months Ended		3 Months Ended
	Mar. 29, 2024	Feb. 21, 2023	Sep. 22, 2021	Mar. 31, 2024
Incentive Plan [Member]
Compensation Description	Company common stock at an exercise price of $3.10 per share, subject to the approval of the Plan Amendment at the Annual Meeting, to the following officers, among other employees, (i) Robert McDermott, Chief Executive Officer and President – options to purchase 1,817,742 shares of Company common stock; (ii) Archit Shah, Chief Financial Officer – options to purchase 482,259 shares of Company common stock; (iii) David Fidanza, Chief Information Officer – options to purchase 352,420 shares of Company common stock; (iv) Muralidar Chakravarthi, Chief Technology Officer – options to purchase 352,420 shares of Company common stock; (v) Jeffery Stellinga, Vice President – options to purchase 352,420 shares of Company common stock
Option bonus related to 2023 performance [Member]
Compensation Description	(i) Robert McDermott, Chief Executive Officer and President – options to purchase 570,754 shares of Company common stock; (ii) Archit Shah, Chief Financial Officer – options to purchase 158,220 shares of Company common stock; (iii) David Fidanza, Chief Operating Officer – options to purchase 152,055 shares of Company common stock; (iv) Muralidar Chakravarthi, Chief Technology Officer – options to purchase 154,110 shares of Company common stock; (v) Jeffery Stellinga, Vice President – options to purchase 34,247 shares of Company common stock and (vi) Carly Garrison, Director of Sales – options to purchase 114,384 shares of Company common stock. In addition the cash awards are subject to the Company successfully raising in excess over $5,000,000 in equity during 2024 to the following officers, amount other employees;(i) Robert McDermott, Chief Executive Officer and President – $125,250; (ii) Archit Shah, Chief Financial Officer – $39,000; (iii) David Fidanza, Chief Operating Officer – $36,750 (iv) Muralidar Chakravarthi, Chief Technology Officer – $37,500; and (v) Carly Garrison, Director of Sales - $21,750
Lease [Member]
Lease Agreement Description			Company signed a six year and one month lease agreement for approximately 7,650 square feet for its new headquarters commencing on January 1, 2022, located in Ocoee, Florida. The lease provides for a five-year renewal term at the option of the Company. In April 2023, the Company entered into a lease agreement with its existing landlord of its Florida location for a lease of an additional 2,295 square feet of space beginning at the earlier of June 1, 2023 or completion of build out for a five year term
Lease Costs				$ 86,178
Cash Paid Measurement Of Lease Liabilities				$ 85,146
Settlement Agreement [Member]
Claimed charge of damages		$ 635,000

CONCENTRATION OF CREDIT RISK (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Fdic Insured Limit	$ 250,000
Revenue Benchmark [Member] \| No Customers [Member]
Concentration Risk, Percentage	10.00%
Accounts Receivable [Member] \| Three Customers [Member]
Concentration Risk, Percentage	31.00%
Accounts Receivable [Member] \| One Customers [Member]
Concentration Risk, Percentage		31.00%

SEGMENT INFORMATION (Details) - USD ($)	3 Months Ended
SEGMENT INFORMATION (Details) - USD ($)	Mar. 31, 2024	Mar. 31, 2023
Total [Member]
Total Revenue	$ 2,723,363	$ 1,840,371
Revenues:
Revenue, Percentage	100.00%	100.00%
Total percent	48.00%
Revenue Segment [Member]
Revenues:
Subscription Software And Services, Percentage Change	52.00%
Professional Services And Other, Percentage Changes	(6.00%)
Subscription Software And Services	$ 2,595,050	$ 1,703,815
Subscription Software And Services, Percentage	95.00%	93.00%
Professional Services And Other	$ 128,313	$ 136,556
Professional Services And Other, Percentage	5.00%	7.00%

BUSINESS COMBINATIONS (Details) - USD ($)	Mar. 31, 2024	Jan. 03, 2024	Jan. 02, 2024	Jan. 01, 2024	Dec. 31, 2023
Cash		$ 12,752	$ 871	$ 0
Accounts receivable			54,259	959
Customer relationships	$ 2,729,920	0	0	0	$ 2,980,412
Acquired technology		678,548	1,154,870	5,299,041
Deferred revenue		8,700
Total assets acquired		700,000	1,210,000	5,300,000
Net assets acquired		700,000	1,210,000	5,300,000
Total Consideration paid		700,000	1,210,000	5,300,000
Cash [Member]
Total Consideration paid		0	370,000	500,000
Notes Payable [Member]
Total Consideration paid		125,000	0	0
Common Share [Member]
Total Consideration paid		0	0	0
Series A Preferred Stock [Member]
Total Consideration paid		$ 575,000	$ 840,000	$ 4,800,000

BUSINESS COMBINATIONS (Details Narrative)	Jan. 02, 2024
Ally Commerce, Inc [Member]
Description of note issued to the Seller	(i) the Company paid to FeatherPay $500,000 in cash, and (ii) the Company agreed to issue to FeatherPay’s stockholders an aggregate of $4,800,000 worth of shares (the “Stock Consideration”) of Company’s Series A Preferred Stock, par value $0.0001 at $10.00 per share totaling 480,000 shares
Teamworx LLC [Member]
Description of note issued to the Seller	(i) the Company paid to Seller $125,000 in cash, and (ii) the Company agreed to issue to Seller $575,000 worth of shares of Company Series A Preferred Stock at $10.00 per share totaling 57,500 shares
Verifi Dental Limited [Member]
Description of note issued to the Seller	(i) the Company paid to Seller $360,000 in cash, and (ii) the Company agreed to issue to Seller $840,000 worth of shares of Company Series A Preferred Stock at $10.00 per share totaling 84,000 shares

SUBSEQUENT EVENTS (Details Narrative) - USD ($)				1 Months Ended	3 Months Ended
SUBSEQUENT EVENTS (Details Narrative) - USD ($)	May 13, 2024	May 08, 2024	Apr. 02, 2024	Apr. 29, 2024	Mar. 31, 2024
Issue of restricted common stock					100,000
Subsequent Event [Member]
Promissory note principal amount			$ 200,000	$ 250,000
Muturity date			Jun. 30, 2024	May 31, 2024
Interest rate			16.00%	12.00%
Subsequent Event [Member] \| Convertible Promissory Note
Principal amount	$ 200,000
Issue of restricted common stock	28,625
Extended date	Jul. 31, 2024
Muturity date	Apr. 30, 2024
Subsequent Event [Member] \| Promissory Note
Principal amount	$ 260,000
Issue of restricted common stock	36,648
Extended date	Jul. 31, 2024
Muturity date	Apr. 30, 2024
Subsequent Event [Member] \| Convertible Promissory Note One
Principal amount	$ 350,000
Issue of restricted common stock	51,539
Extended date	Jul. 31, 2024
Muturity date	May 13, 2024
Purchase Agreements [Member] \| Subsequent Event [Member]
Common stock share issue the investors		17,034
Convertible notes aggregate principal amount		$ 304,700
Conversion price		$ 1,416
Aggregate principal amount		$ 304,700
Aggregate gross proceeds		$ 277,000
Discount rate		10.00%
Description of agreement		A holder shall not have the right to convert any portion of a Note to the extent that, after giving effect to such conversion, the holder (together with certain related parties) would beneficially own in excess of 4.99%, or the “Maximum Percentage”, of shares of the Company’s common stock outstanding immediately after giving effect to such conversion. If the Company fails to make any Amortization Payments when due, then each holder may alternatively elect to convert all or any portion of such holder’s Notes at a conversion price equal to the lesser of (i) the Conversion Price, and (ii) 90% of the lowest VWAP of the common stock during the five (5) consecutive trading days immediately prior to such conversion